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7ABBREVIATIONS 
CFU   colony forming unit 
DNA   deoxyribonucleic acid 
GALT   gut-associated lymphoid tissue 
IBD   inflammatory bowel disease 
i.v.   intra venous 
MAC   microflora-associated characteristics 
MRSA  methicillin-resistant Staphylococcus aureus
NCCLS  National Committee for Clinical Laboratory Standards 
PCR   polymerase chain reaction 
PFGE   pulsed-field gel electrophoresis 
p.o.   per oral 
rRNA   ribosomal ribonucleic acid 
SIBO   small intestinal bacterial overgrowth  
TGGE  temperature-gradient gel electrophoresis  
TEM  class of plasmid-mediated β-lactamases (first isolated from a patient 
named Temoniera) 
TRBL   targeted recombinant β-lactamase   
VRE   vancomycin-resistant enterococci 
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ABSTRACT 
Background: The intestinal microbiota affects many physiological and 
immunological functions of the body and is closely connected to the homeostasis and 
health status of an individual. Due to difficulties in obtaining samples from the 
intestine and studying complex microbial populations the knowledge of the 
composition, dynamics and metabolic potential of microbial populations in the upper 
gut is limited. Antimicrobials may disrupt the balance of the microbiota by causing 
quantitative and qualitative changes such as emergence and enrichment of antibiotic-
resistant populations, and decrease in colonisation resistance against pathogens. The 
aims of this study were to analyse cultivable jejunal microbiota of a dog in detail and 
compare it to faecal findings, and to evaluate the ability of oral β-lactamase 
administration, targeted to degrade intestinal ampicillin residues, to prevent 
ampicillin-induced changes in the intestinal microbiota. 
Material and methods: Jejunal and faecal samples were obtained from healthy 
laboratory beagles with permanent jejunal fistula randomised into 3 treatment groups 
receiving ampicillin, ampicillin + β-lactamase or placebo. Samples were collected 
before, during and after the treatment and analysed using bacterial culture and TGGE 
(temperature-gradient gel electrophoresis) for total bacterial counts and composition 
of the dominant microbiota. Susceptibility testing and PCR for detection of TEM gene 
were the methods for monitoring resistance rates. In addition, jejunal and serum 
ampicillin concentrations were determined. 
Results: The relative quantities of predominant bacterial groups, proportion of 
anaerobes, intra- and inter-individual species variety and stability of the microbiota 
differed significantly between the jejunum and faeces. Oral β-lactamase inhibited the 
effects of ampicillin, monitored as significant differences in resistance rates and 
9bacterial composition during treatment between the groups receiving ampicillin with 
and without β-lactamase.  
Conclusion:  This study suggests that faeces with stable and rich microbiota does not 
represent jejunal microbiota that is characterised as harbouring few individually 
varying bacterial species at a time with fluctuating counts. Oral β-lactamase has 
potential in inhibiting the adverse effects of β-lactam therapy. 
Keywords: gastrointestinal tract, jejunum, microbiota, β-lactams, susceptibility  
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TIIVISTELMÄ 
Taustaa: Suolistomikrobisto vaikuttaa moniin kehon fysiologisiin ja immunologisiin 
toimintoihin ja siten myös kehon tasapainotilaan sekä yksilön terveyteen. Johtuen 
vaikeuksista näytteiden saamisessa suoliston eri osista sekä monimuotoisten 
mikrobipopulaatioden tutkimisen hankaluuksista, ymmärtämys suolistomikrobiston 
koostumuksesta, dynamiikasta ja metaboliikasta on vaillinaista. Antibiootit voivat 
häiritä mikrobiston tasapainoa aiheuttaen niin määrällisiä kuin laadullisia muutoksia 
mikrobistossa kuten antibiootille vastustuskykyisten mikrobien ilmaantumista ja 
rikastumista ja taudinaiheuttajamikrobien kolonisaatioresistenssin alenemista. Tämän 
tutkimuksen tavoitteena oli analysoida koiran ohutsuolen mikrobisto 
yksityiskohtaisesti viljelymenetelmää käyttäen ja verrata sitä ulosteen mikrobistoon. 
Lisäksi tavoitteena oli arvioida suun kautta annettavan, suolistoon kulkeutuvien β-
laktaamiryhmän antibioottijäämien hajoittamiseen suunnitellun β-
laktamaasivalmisteen tehoa ampisilliinin suolistomikrobistossa aiheuttamien 
muutosten ehkäisyssä.  
Materiaalit ja menetelmät: Ohutsuolen sisältö ja ulostenäytteet kerättiin terveiltä 
beagle-koirilta, joille oli tehty pysyvä fisteli (permanent jejunal fistula). Koirat oli 
satunnaistettu kolmeen hoitoryhmään, jotka saivat joko ampisilliiniä, ampisilliiniä ja 
β-laktamaasia tai lumevalmisteita. Näytteet kerättiin ennen antibioottikuuria, kuurin 
aikana ja sen jälkeen ja analysoitiin käyttäen viljelyä ja TGGE-profilointia 
(temperature-gradient gel electrophoresis) bakteerien kokonaismäärien ja 
koostumuksen tutkimiseen. Antibioottiresistenssin esiintymistä seurattiin 
herkkyysmäärityksin sekä TEM-geenin (plasmidi-välitteinen β-laktamaasigeeni) 
esiintymistä PCR-määrityksin. Lisäksi seurattiin ohutsuolen sisällön sekä seerumin 
ampisilliinipitoisuuksia.     
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Tulokset: Vallitsevien bakteeriryhmien suhteelliset osuudet, anaerobisten bakteerien 
osuus, yksilöiden sisäinen sekä yksilöiden välinen lajivaihtelu ja mikrobiston 
stabiilius erosivat merkittävästi ohutsuolen ja ulosteen mikrobistojen välillä. β-
laktamaasivalmiste ehkäisi ampisilliinin vaikutuksia: teho havaittiin merkittävinä 
eroina resistenssin esiintymisessä ja mikrobiston koostumuksessa ampisilliinia ja 
ampisilliiniä sekä β-laktamaasivalmistetta saaneiden ryhmien välillä.   
Johtopäätökset: Tämä tutkimus osoittaa, että ulosteen melko stabiili ja runsas 
mikrobisto ei edusta ohutsuolen rajoittunutta, yksilöittäin, ajallisesti, määrällisesti ja 
laadullisesti vaihtelevaa mikrobistoa. β-laktamaasi on lupaava valmiste β-
laktaamiantibioottien aiheuttamien epäsuotuisten vaikutusten ehkäisyyn. 
Avainsanat: suolistomikrobisto, ohutsuoli, β-laktaamit, mikrobilääkeherkkyys 
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INTRODUCTION 
The intestinal microbiota is known to have a crucial impact on the health status of an 
individual. Microbes influence functions such as nutrition, development and 
maintenance of the immune system, and defence against pathogens. To understand the 
relationship between the intestinal microbiota and health, and the metabolic potential 
of the microbes, and to evaluate the effect of different diets, treatments or medical 
conditions on the microbiota, fundamental knowledge of the intestinal microbial 
populations is needed. 
Because of the inaccessibility of the intestine, there are major difficulties in studying 
the intestinal microbiota in its natural habitat and most studies of the intestinal 
microbiota have been done using faecal samples. Due to low number of studies data 
on the differences between the microbiota of different parts of the gut are limited. The 
microbiota of the human upper gut and caecum has been reported to differ 
significantly from that of the colon and faeces (Gorbach et al. 1967, Justesen et al.
1984, Simon & Gorbach 1986, Marteau et al. 2001). However, the recoverability of 
small intestinal microbiota from faeces has not been fully analysed.     
Bacterial composition, activities and concentrations can be severely distorted by 
outside agents such as antimicrobials. Exposure of gut microbiota to antimicrobials 
selects resistant bacteria that may enrich and spread within a given surrounding 
(Livermore 2003, Münnich & Lübke-Becker 2004, Drazenovich et al. 2004). 
Increasing rates of antimicrobial resistance following extensive use of antimicrobials 
has led to a worldwide interest in finding ways to inhibit the emergence of resistance.
The present study was done in order to make a detailed analysis on the canine jejunal 
microbiota and compare it with corresponding faecal microbiota in 22 beagle dogs 
with permanent jejunal fistula. The other aim of the study was to analyse the effect of 
i.v. ampicillin treatment on the intestinal microbiota, especially on the antimicrobial 
resistance of coliforms, and to analyse whether the adverse effects of ampicillin could 
be inhibited by simultaneous oral administration of β-lactamase, designed to degrade 
antibiotic residues in the gut. The analyses were performed using culture method and 
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various molecular tools (TGGE, quantitative PCR, PFGE). The ultimate aim of the 
study was to contribute to the better understanding of the composition and dynamics 
of the gut microbiota, and to the development of means to prevent antimicrobial 
resistance.
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REVIEW OF THE LITERATURE 
1. Gut microbiota in health and disease 
1.1. The importance of microbes 
Microorganisms colonise all mucosal surfaces forming a complex and dynamic 
entities. The intestine harbours the vast majority of the microbes of the body, and 
there the microbes also have the most prominent impact on our health. The gut 
microbiota can be described to be in a state of unstable stability with reference to the 
relatively stable composition of the host specific main bacterial groups and their 
proportions within an individual, and to the simultaneous constant flow of new 
bacterial clones co-existing and replacing the previous ones in a balanced and 
seemingly homologous living system (McCartney et al. 1996, Franks et al. 1998, 
Zoetendal et al. 1998, Falk et al. 1998). Gut microbiota can be regarded as a 
metabolically active organ of the body, beneficial to both microbes and the host. 
Compared to skin, the contracting gastrointestinal tract with villi and microvilli 
comprises 100-fold surface area (2 m2 versus 150-200 m2, respectively) providing a 
considerable amount of space for digestive and physiological processes (Van Dijk 
1997, Waldeck 1990). The vital importance of the microbiota to the homeostasis of 
the body is obvious since the imbalance of the microbiota may cause several different 
disturbances of the gastrointestinal functions such as diarrhoea and impairs the health 
status of an individual.  
Microbiota has crucial role in many physiological/biochemical and immunological 
functions of the body (Gordon & Pesti 1971, Berg 1996). The importance of the 
microbiota has been analysed by comparisons of germ-free (sterile) and conventional 
animals, most often mice, rats, or chickens. Individuals grown in a microbe-free 
(sterile) environment lack many features of the immune system, require 30% more 
calories to maintain body mass and die sooner than those grown in normal conditions 
(Gordon & Pesti 1971, Wostmann et al. 1983, Tanaka & Ishikawa 2004, Bäckhed et 
al. 2004). The features being altered by bacterial activity, differing between germfree 
and conventional mice, are collectively known as microflora associated characteristics 
(MACs) (Midtvedt 1989). In turn living microbes in the intestine are provided a niche 
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with abundance of nutrients and fermentable carbon sources originating from host 
secretions, diet, cast off epithelial cells and mucin. Additionally, the conditions are 
stable, warm and humid. 
1.2. The effects of intestinal microbiota   
To colonise different niches of the intestinal tract microbes have acquired distinct and 
appropriate adaptation strategies. The commensal and symbiotic (indigenous) 
microbes are those that are beneficial or at least not harmful to the host in contrast to 
the harmful pathogenic (transient) species. In addition to the immunopotentiation 
(maturation of the gut-associated lymphoid tissue, GALT) the commensal bacteria 
play a significant role in the nutrition by degrading otherwise non-digestible food 
compounds, producing vitamins and short-chain fatty acids, used as an energy source 
by the colonic mucosa, conversion of urobilin to urobilinogen, conversion of 
cholesterol to coprostanol, and in absorption of ions (Moore & Holdeman 1974, 
Mackowiak 1982, Simon & Gorbach 1986). The gut-associated lymphoid tissue 
(GALT) contains over 80% of all B-cells (antibody producing lymphocytes) of the 
body and more lymphoid cells than the spleen, peripheral lymph nodes and blood 
together (Brandtzaeg et al. 1989). The increasing frequency of atopic allergies has 
been linked to overly hygienic living conditions, referred to as the hygiene hypothesis, 
altering the colonisation patterns in infancy and leading to lack of tolerance to 
harmless food proteins and antigens (Wold 1998). Indigenous bacteria also stimulate 
vascularisation and development of intestinal villi, have an important role in the 
metabolism of endogenous and exogenous compounds (detoxification), and in 
prevention of colonisation and proliferation of pathogens and opportunistic microbes 
(Hooper et al. 2002, Stappenbeck et al. 2002). Term colonisation resistance was 
introduced by van der Waaij et al. (1971). It provides non-specific defence against 
infections and includes various bacterial mechanisms such as competitive exclusion 
(competition of living/adhesion space and nutrients) and production of substances 
harmful to pathogens (antimicrobial agents, bacteriocins) as well as anatomical and 
physiological features of the host (mucosa, secretions, gastrointestinal motility). Most 
effects of bacteria against other bacteria are strictly local since e.g. bacteriocins are 
degradable by host digestive enzymes (Guarner & Malagelada 2003).  
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1.3. Dysfunctions of the gut microbiota in humans 
Clinical disturbances 
Whether the causes for dysfunctions in the intestine are of physiological or exogenous 
origin, they are often associated with gastrointestinal tract infections with altered 
bacterial composition, bowel movements, and/or water and ion balance. The clinical 
terms for gastrointestinal tract infections are gastroenteritis, diarrhoea, dysentery and 
enterocolitis, each with distinctive set of clinical manifestations (Mims et al. 1998).  
One of the most common type of chronic gut dysfunction, the inflammatory bowel 
disease (IBD), has been linked to loss of tolerance to commensal bacteria. Intestinal 
bacteria may be involved in maintaining the inflammation reaction in IBD (e.g. 
ulcerative colitis, Crohn’s disease) since patients have increased mucosal secretion of 
IgG antibodies against several commensal bacteria and have higher amounts of 
bacteria attached to their epithelial surfaces compared with healthy people 
(Macpherson et al. 1996, Swidsinski et al. 2002).  
Another serious clinical condition possibly linked to disturbances in gut microbiota is 
colon cancer. By production of potentially toxic or carcinogenic substances such as 
amines, phenols and indols, intestinal bacteria are most likely one of the factors 
modulating the risk of initiation of colon cancer (Smith & Macfarlane 1996, 
Macfarlane & Macfarlane 1997). Increase in the incidence and growth rate of colonic 
tumors have been shown to be associated to some Bacteroides and Clostridium
species while probiotic bifidobacteria bacteria prevent tumorigenesis in rats and mice 
(Onoue et al. 1997, Horie et al. 1999, Singh et al. 1997). Similarly, the presence of 
Bacteroides vulgatus and Bacteroides stercoris has been connected with a high risk of 
colon cancer whereas Lactobacillus acidophilus, Lactobacillus S06 and Eubacterium 
aerofaciens (currently Collinsella) associate with a low risk in humans (Moore & 
Moore 1995). Short-chain fatty acids produced by bacterial fermentation have been 
associated with reduction in the incidence of colon cancer and IBD (Wachtershauser 
& Stein 2000, Blottiere et al. 2003, Miyauchi et al. 2004). 
19
Small intestinal bacterial overgrowth 
In small intestinal bacterial overgrowth (SIBO), also called the contaminated small 
bowel syndrome, total bacterial counts exceed those of healthy subjects by 1-2 log 
difference, usually crossing the limit of 105 cfu/g  (Finegold & George 1989, Stotzer
et al. 1998, Corazza et al. 1990). Patients with SIBO may have no symptoms and no 
predisposing factors, or may suffer from clinical manifestations such as malabsorption 
of lipids, amino acids and carbohydrates, vitamin B12 deficiency, and disturbance in 
water and electrolyte transport in enterocytes (Gracey 1983). The causes and 
pathogenesis of the SIBO are poorly understood but several factors promoting 
manifestations have been identified. They include pathological abnormalities of the 
intestinal tract, stagnation of bowel contents, decreased gastric acidity, antimicrobial 
therapy and impaired immune system (Finegold & George 1989, Gracey 1983). 
SIBO, as well as increased permeability of the intestinal mucosal barrier and 
deficiencies in host immune defences (e.g. mucin and secretory IgA production) are 
thought to promote bacterial translocation, i.e. the crossing of bacteria through the 
host epithelial mucosa (Berg 1999, Macpherson et al. 2000). Bacterial translocation 
enables bacteria to transfer within the body causing local infections, sepsis, shock, 
multisystem organ failure, or death of the host (Guarnier & Malagelada 2003). 
Delayed small intestinal transit times, possibly promoting small intestinal overgrowth, 
has been recorded in several conditions with high incidences of bacterial translocation 
such as obstructive pancreatitis, hepatic failure, and portal vein obstruction (Moody et
al. 1995, Wang et al. 1994, Yi et al. 1999).  
2. Composition of the human gut microbiota 
2.1. General features 
The mammal gut microbiota is composed of up to 1000 bacterial species with 30-40 
species comprising the majority (99%) at a time, and with a particular individual 
combination of predominant species and unique strains distinct from other individuals 
(Savage et al. 1968, Savage 1977, Lee et al. 1971, Moore & Holdeman 1974, Xu & 
Gordon 2003). 
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The stability of the microbiota is challenged by gastric, pancreatic, and biliary acid 
secretions, peristaltic activity and continuous turnover of the epithelium and the 
mucus layer. On the other hand, peristaltic movement of the gut induces the exposure 
of different segments of the gut to the varied components of the intestinal contents 
ensuring the continuous beneficial interaction of microbiota, dietary molecules, 
epithelium and gut-associated immune system (Falk et al. 1998). The most numerous 
bacteria in the gut are obligatory anaerobic species accompanied by smaller amounts 
of aerobic/facultative bacteria with aerobes comprising only 1:100 - 1:1000 of the 
total count in the intestinal lumen (Finegold et al. 1983, Berg 1996). However, the 
proportion of aerobic species varies between the different regions of the intestinal 
tract.  
Table 1. Microbial densities in different parts of the digestive tract (Simon & 
Gorbach 1984, Berg 1999, Marteau et al. 2001). 
Site Bacterial count (cfu/ml, cfu/g) 
Oropharynx 108-11
Stomach 0-104
Small intestine  
Duodenum 0-104
Jejunum 0-105
Ileum 104-8
Caecum 106-8
Colon 1010-12
Microbial densities are low in the stomach, and in the proximal and middle small 
intestine (duodenum, jejunum) because of the low pH and peristalsis (Table 1). The 
counts and diversity of the microbiota increase towards the distal small intestine 
(ileum) and colon (Savage 1977, Berg 1996). The small intestinal transit time is only 
2-4 h compared with up to 60 h in the colon (Holzapfel et al. 1998, Drasar & Mill 
1974). In the colon pH is higher than in the upper small intestine, the turnover is 
slower, redox potential is lower, short-chain fatty acid concentration is higher and the 
bacterial load is higher, indicating unique conditions in each gut compartment 
(Mackie et al. 1999). There is a shift in the biochemical atmosphere also within the 
colon between proximal colon with intense fermentation, rapid bacterial growth and 
pH of 5-6 and distal colon with lower fermentable substrate availability, putrefactive 
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processes, slow bacterial growth and neutral pH (Cummings & Macfarlane 1991, 
Tannock 1999a, Guarner & Malagelada 2003).  
The conditions in the lumen differ also from those proximal to the mucosa. The gut 
can be divided crosswise into four different microhabitats: lumen, mucus layer, deep 
mucus layer and mucosal epithelial cells (Berg 1996). These microhabitats provide 
separate niches with unique properties. The predominant bacterial species associated 
to the jejunal, ileal and colonic mucosa differ significantly from the respective jejunal 
or ileal lumen and faecal bacterial community, and additionally bacterial counts 
between separate mucosal sites vary considerably (Bhat et al. 1980, Zoetendal et al.
2002, Wang et al. 2003). The mucosa-associated bacteria in colon and rectum are 
fairly similar in total counts and species composition (Poxton et al. 1997). The 
analysis of the mucosal microbiota is complicated by the undefined effects on the 
bacteria caused by the evacuation of the intestine preceding the biopsy collection and 
the possible washing procedures at sampling. A very limited number of studies has 
focused on the differences between the bacterial composition and activities in the 
different gut compartments.  
2.2. Species composition 
The composition of the microbiota is known to be affected by several factors 
concerning the host such as age, diet, medication, health status, microbes in the 
environment and stress, as well as factors concerning the microbes such as growth 
rate, nutritional and adherence characteristics and microbial interactions (Holzapfel et 
al. 1998, Mitsuoka 1992). In addition, also host genetics have been reported to have 
significant correlations between bacterial communities (van der Merwe et al. 1993, 
Toivanen et al. 2001, Zoetendal et al. 2001). Once established, the microbiota remains 
relatively constant over time in adults (Finegold et al. 1983). Community shifts within 
the microbiota occur throughout the lifespan, especially in infants and in elderly 
people (Mitsuoka 1992, Hopkins et al. 2001, Favier et al. 2002).
As the composition of the microbiota is influenced by external factors such as 
acquisition of microbes in the diet, manipulating the microbiota from outside in order 
to improve the health of the host has drawn much attention (Mackie et al. 1999). The 
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concept of bacterial therapy using microbial cocktails has been introduced and it has 
shown to be a promising method to treat and prevent various respiratory and 
gastrointestinal tract infections (Huovinen 2001).  
The cultivable dominating fecal bacteria belong to genera Bacteroides, 
Bifidobacterium, Eubacterium and related genera, Clostridium, Peptococcus, 
Peptostreptococcus and related genera, Fusobacterium and Ruminococcus, whereas 
the subdominant family and genera comprise of facultative anaerobes (aerobes) such 
as Enterobacteriacae, Streptococcus, Enterococcus, Lactobacillus and Proteus (Table
2) (Simon & Gorbach 1984, Tannock 1999c). Some of these genera, especially 
Eubacterium, anaerobic gram-positive cocci and Clostridium have gone through 
extensive taxonomic revisions on the basis of new molecular methods (DNA-DNA 
hybridisation, 16S rRNA sequencing) that are replacing phenotypic methods as means 
to classify microbes. Molecular methods have also provided new aspects to the 
quantitative relations between different bacteria by determining proportions of group 
specific rRNA of total rRNA of a microbiota (Table 3). Attempts to combine culture-
based data with molecular methods-based data has not yet provided us an accurate 
picture of the numerically predominant active species in the gut. Based on the partial 
sequencing of 16S rRNA, most of the bacteria found in the human colon fall into four 
phylogenetic clusters consisting of (1) Bacteroides, (2) Bifidobacterium and other 
gram-positive bacteria with high G+C content, (3) Clostridium coccoides and 
relatives (Coprococcus, Eubacterium, Lachnospira, Ruminococcus), and (4) 
Clostridium leptum and relatives, fusobacteria, and the Atopobium group (Wilson et
al. 1997). 
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Table 2. Examples of common cultivable inhabitants of the adult human intestine 
(Moore & Holdeman 1974, Holdeman et al. 1976, Finegold et al. 1983, Sneath et al.
1986, Murray et al. 2003).   
Genus / Group Common representatives 
Anaerobic 
Bacteroides B. fragilis group, B. splanchnicus  
Clostridiuma C. perfringens, C. sordellii, C. bifermentans, C. innocuum 
Bifidobacterium B. adolescentis, B. longum B. infantis, B. breve 
Eubacteriumb E. rectale, Eggerthella lenta, Collinsella aerofaciens, 
Mogibacterium timidum 
Gram-positive coccic P. anaerobius, P. micros, P. asaccharolyticus, 
Ruminococcus 
Gram-negative cocci Veillonella parvula, Acidaminococcus fermentans, 
Megasphaera elsdenii 
Fusobacterium  F. necrophorum, Faecalibacterium prauznitziid
Facultative/ aerobic
Lactobacillus L. acidophilus, L. casei, L. rhamnosus 
Enterobacteriacae Escherichia coli, Klebsiella, Enterobacter 
Streptococcus S. bovis, S. anginosus, S. salivarius 
Enterococcus E. faecalis, E. faecium 
Corynebacteria Corynebacterium, Arcanobacterium, Actinomyces, Rothia 
Yeasts Candida albicans, Saccharomyces, Geotrichum  
a Divided into phylogenetic clusters (C. coccoides, C. leptum)
b Genera Atopobium, Collinsella, Eggerthella, Mogibacterium,  Slackia have been 
reclassified from Eubacterium.
c Anaerobic gram-positive cocci includes genera Anaerococcus, Coprococcus, 
Finegoldia, Micromonas, Peptococcus, Peptoniphilus, Peptostreptococcus, 
Ruminococcus.  
d Formerly Fusobacterium prausnitzii
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Table 3. Mean proportions of different bacterial groups of the total microbial 
population in human feces detected by 16S rRNA hybridisation with group specific 
probes. 
Bacterial group 
(probes)
Matsuki et 
al. 2002 
Sghir et al.
2000
Rigottier-
Gois et al.
2003 
Franks et al.
1998 
Bacteroides
(Bacto1080, Bfa602, 
Bdis656, Bact338) 
39% 37% 42% 20% 
Clostridium coccoides
(Erec482) 
22% 14% 22% 29% 
Clostridium leptum
(Clept1240)
8% 16%   
Low GC  
(Strc493, Lacto722) 
 1%  12% 
Bifidobacterium
(Bif228, Bif164, 
Bif1412) 
7% <1% 3% 3% 
Enterobacteria  
(Enter 1432) 
 <1% 1%  
Prevotella 
(Prevo0803) 
6%    
Faecalibacterium 
prausnitzii (Fprau645)
  9%  
2.3. Upper gut microbiota 
In contrast to the heavily and steadily colonised lower regions of the intestinal tract, 
stomach and upper small intestine (duodenum, jejunum) harbour microbes in more 
time dependent manner. Both are practically free of cultivable living microorganisms 
when they are empty but harbour small numbers (101-3 cfu/ml) of organisms at least 
transiently with highest numbers shortly after eating. The sparse microbiota in the 
upper small intestine is thought to consist mostly of oropharyngeal origin with major 
components being gram-positive acid tolerant lactobacilli, streptococci, fungi and 
staphylococci, and a minority of gram-variable veillonella, fusiforms, clostridia, 
actinomycetes, corynebacteria and haemophilus (Gorbach et al. 1967, Justesen et al.
1984, Berg 1996, Sullivan et al. 2003). The number of bacteria attached to the 
epithelia is also lower and consists of more gram-positive organisms compared to 
large intestine (Plaut et al. 1967, Guarner & Malagelada 2003). Whether the bacteria 
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found are only transient passengers or represent true colonisers of the upper small 
intestine is unclear.  
In the distal small intestine (terminal ileum) the counts (104-8 cfu/ml) and diversity, 
including appearance of substantial numbers of coliforms and bacteroides, increase 
drastically (Drasar & Mill 1975, Hentges 1993). The predominantly gram-positive 
bacteria of the upper small intestine shifts to gram-negative predominance towards the 
colon (Gorbach et al. 1967). In addition to declining acidity, the microbiota in the 
ileum is affected also by reflux of caecal contents (Gorbach et al. 1967, Nord & Kager 
1984). The small intestine has been thought to harbour a distinct and characteristic 
microbiota but the composition of it has not been fully described. Ileal samples 
obtained by intubations and small intestinal samples obtained by needle aspiration 
grew total counts of 103-6 cfu/ml, with Bacteroides and anaerobic gram-positive rods 
such as Bifidobacterium dominating over enterococci and coliforms (Gorbach et al.
1967, Finegold et al. 1983). In the caecum aerobic species such as Escherichia coli,
enterococci, and lactobacilli, comprise a significantly larger part of the total bacterial 
count (108 cfu/ml), covering 50% of total bacterial rRNA, compared to faeces where 
aerobes cover 7% of the total count (1010 cfu/ml), respectively (Marteau et al. 2001).
2.4. Opportunistic commensals 
Opportunistic commensals are the bacteria that are frequently present as permanent 
members of the microbiota but under favourable circumstances may proliferate 
vigorously and turn pathogenic. Although the vast majority of the normal microbiota 
consists of anaerobic bacteria most endogenous infections are caused by aerobes such 
as enterobacteria and enterococci (Vollaard & Clasener 1994). Common anaerobic 
genera such as Bacteroides and Clostridium include species with known 
pathogenicity; B. fragilis is the most frequent clinical isolate (Namavar et al. 1989) 
and C. difficile can exist as a harmless commensal in infants but cause disease 
especially in hospitalised elderly (Stark et al. 1982, Poxton 2005). Opportunistic 
bacteria may produce toxic metabolites causing disorders when accumulated. Some 
bacteria and fungi, e.g. species of Neisseria, Bacteroides, Streptococcus and Candida
have the ability to change surface antigenicity in order to evade host immune 
responses (Deitsch et al. 1997, Kuwahara et al. 2004). Bacteria that are seldom 
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associated with infections such as Bifidobacterium, Eubacterium and Lactobacillus 
species can also occasionally cause serious illnesses (Brook & Frazier 1993). 
Coliforms 
One of the predominating bacterial groups in the human and animal intestine is 
coliforms, i.e. gram-negative aerobic fermentative rods, with E. coli being the most 
common and most studied. It is also considered an indicator of faecal contamination 
in food and water. Although E. coli may not cover more than a fraction (<1%) of the 
total count of the intestinal bacteria, it is significant as a pathogen being one of the 
main causes of nosocomial infections, main causative of urinary tract infections and 
an important cause of diarrhoea (Eisenstein & Zaleznik 2000, Whittam et al. 1993,
Maslow et al. 1995). E. coli has acquired several pathogenic mechanisms by which 
diarrhoeagenic strains can be divided into four distinct groups: enterotoxigenic 
(ETEC), enteroinvasive (EIEC), enterohaemorrhagic (EHEC), and enteropathogenic 
(EPEC) E. coli (Mims et al. 1998). On the other hand, non-pathogenic E. coli may 
contribute to the preservation of colonisation resistance and has been given as 
bacterial probiotic therapy to patients with ulcerative colitis and in prevention of 
colonisation of antibiotic-resistant E. coli strains in premature babies and in 
prevention of neonatal calf diarrhea  (Rastegar et al. 1990, Rembacken et al. 1999,
Kruis et al. 2004, von Buenau 2005).  
Fungi
Fungi, most often yeasts, are normally present in small amounts in the intestine and 
faeces of mammals. In immunodeficient patients or when bacteria are suppressed by 
antimicrobials, yeasts (Candida, Cryptococcus spp.) may overgrow the intestine and 
act as pathogens causing diarrhoea, abdominal cramps and infections in other body 
sites (Krause et al. 2001, Tortorano et al. 2004). Yeasts can also be probiotic. In 
treating antibiotic associated diarrhoea Saccharomyces boulardii serine protease has 
been demonstrated to inhibit the pathogenic effects of C. difficile toxins A and B on 
human colonic mucosa (Castagliuolo et al. 1999). 
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3. The digestive tract and intestinal microbiota of dog 
The development of microbiota begins at birth when the sterile foetus is colonised in 
the birth canal and by the immediate environment. The bacterial succession is similar 
in the human and canine intestine with the very first colonisers originating from the 
mother, followed by microbes benefiting from breast-feeding and then drastically 
changing towards obligate anaerobes and greater diversity as solid foods are 
introduced (Benno et al. 1992a, Mackie et al. 1999). The most numerous colonisers in 
beagles during the first year are bacteroides, eubacteria, bifidobacteria, lactobacilli 
and anaerobic cocci while clostridia and streptococci increase later (Benno et al.
1992a). 
Since dogs are carnivorous the total length of their intestine in relation to the body 
length is somewhat shorter and the motility slower than in humans (Figure 1). As a 
whole the digestive tract of dog, however, resembles that of humans and the 
physiology is similar in many ways. Like humans dogs utilise intestinal microbiota in 
their physiology and both are homothermic mammals. The pH values in the different 
compartments of the digestive tract are also comparable to those of human: the pH in 
the dog stomach is 3, in duodenum and jejunum 6, in ileum 7.5, in colon 6.5 and in 
feces 6.2 (Smith 1965).  
The main cultivable bacterial groups and most common findings in humans and dogs 
are the same including clostridia, bacteroides, streptococci, coliforms, enterococci, 
lactobacilli and veillonellae with increasing counts towards the large intestine (Smith 
1965, Davis et al. 1977, Benno et al. 1992b, Greetham et al. 2002, Buddington 2003, 
Rinkinen et al. 2004). Most intestinal pathogens cause similar clinical symptoms in 
dogs as in humans (C. difficile, multiresistant gram-negatives, enterococci, 
staphylococci). Due to the ability of microbes to adapt and specify to niches with 
unique characteristics there are differences between the bacterial species level 
composition in different mammals. The most common intestinal dysfunction in dogs 
is diarrhoea. Another common disturbance, small intestinal bacterial overgrowth, 
composing of E. coli, enterococci and clostridia is associated with raised serum folate, 
reduced serum vitamin B12 concentrations and altered mucosal permeability and 
function (Batt et al. 1983, Rutgers et al. 1996).
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Figure 1. Gastrointestinal tract of dog and human including stomach, small intestine, 
caecum and large intestine (Adopted from Stevens & Hume 1998). 
Dog      Human
(Canis familiaris)   (Homo sapiens)
Body length 90 cm   Body length 180 cm 
29
4. Obtaining samples from the intestine 
4.1. Getting representative samples from the upper gut 
Studies of microbiota in vivo carry some limitating factors associated to the 
complexity of the ecosystem leading to difficulties in identifying and determining the 
functions of all members or subpopulations. These include the unknown dynamic 
interactions within the microbiota and between microbes and host, inherent 
differences in the microbiota between study subjects, natural variability of the 
microbial strain composition with time, bacterial contamination during intervention 
trials between controls or staff and study group, and differences in human and 
experiment animal microbiota/physiology (Corpet 1987, Zoetendal et al. 2004).  
Apart from general difficulties in analysing complex microbial populations, the 
difficulty in studying the gut microbiota lies in the inaccessibility of the microbiota in 
its natural habitat. Samples from intestinal contents from living healthy subjects 
obtained without anaesthesia and fasting, preoperative antibiotic prophylaxis, or 
laxatives/purgatives are simply not available. After any of these procedures the 
microbiota is no more in its natural state and may have gone through vast 
modification, and the sample size may also remain minimal. In addition, anaesthesia 
slows down the peristaltis, which makes backflow possible, and subjects studied at 
surgery have gastrointestinal dysfunctions and do not represent healthy individuals 
(Borriello et al. 1978). Attempts to get samples from the intestine without surgery 
include self-closing enterocapsules, tubes, endoscopes and, in animals, cannulation 
(Hirtzmann & Reuter 1963, Shiner et al 1963, Gracey 1977, Hill 1996, Stotzer 1998). 
Capsules that pass through the intestine or tube that remains in place allow bacteria to 
multiply before the sample is processed. Invasive techniques going through other 
segments of the digestive tract carry the risk of contamination on the way. Tubes may 
also alter the intestinal motility and the position of the tube may be difficult to 
determine (Donaldson 1964).  
Thus most analyses of the intestinal contents or biopsies are from the caecum or colon 
and originate from diseased persons (Gillian et al. 1992), sudden death victims 
(Macfarlane 1992) or are focused on certain probiotics (Alander et al. 1997, Alander
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et al. 1999, Johansson et al. 1993) or sulphate reducers (Zinkevich et al. 2000). Very 
few studies have analysed the small intestinal microbiota of healthy subjects, and 
limited data are thus available (Marteau et al. 2001).   
Because of these difficulties in obtaining proper samples from different parts of the 
intestinal tract, especially from the upper gut, and ease in collecting faecal samples, 
faeces is often the chosen sample type in studies of the gut microbiota. However, the 
faecal microbiota represents merely the distal colon, not even the proximal colon or 
terminal ileum, and may not represent the upper intestinal microbiota or the metabolic 
activities of it. Moreover, faecal predominant species tend to overgrow subdominant 
bacteria and the selectivity of selective agar media may be poor which makes it very 
difficult to gain isolates for further identification and to characterise the true bacterial 
diversity in faecal samples. Molecular methods with higher sensitivity can be used to 
detect the subdominant microbes but for further characterisation bacterial isolates 
should be obtained by culture.  
4.2. Jejunal fistula 
To overcome the inaccessibility of the intestine, a dog fistula model was designed to 
gain an easy access to jejunal chyme without causing pain to the animal or disturbing 
the normal functions of the gut (Wilsson-Rahmberg & Johnsson 1997, Harmoinen et 
al. 2001). The fistula is created using a 25 cm segment of the dog’s own intestine by 
intussusception. The free ends of the intestine are connected by end-to-end 
anastomosis, and the isolated intestinal segment is inserted by end-to-side anastomosis 
to the intestine extending through abdominal cavity to connect the intestine to the skin 
with proximal end of the segment facing the skin. Small intestinal content (jejunal 
chyme) can be collected pre- or post-feeding without aspiration by inserting a silicon 
tube through the nipple valve into the intestine. A nipple valve can be surgically 
inserted to desired site at the small intestine. The closer the fistula is to the pylorus the 
more running (liquid) the content is (Harmoinen 2004). Most productive samples are 
obtained shortly after feeding (1-4 h) depending on the site of the fistula. Small 
intestinal samples from permanent fistula operated dogs can be obtained without any 
sedation/anaesthesia while the dog is fully active and standing. The fistula operation is 
reported not to have any significant effect on the intestinal motility, measured as 
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transit percentage of barium-impregnated polyethylene spheres, or on the cultivable 
microbiota (Harmoinen et al. 2001).   
5. Analysing the microbiota 
5.1. Microscopic methods 
Microscopic methods can be valuable in analysing bacterial numbers (Kepner & Pratt 
1994). However, microscopic counts do not necessarily correlate with the plate count. 
Plate count detects only reproducible cells whereas with microscopy it is possible to 
enumerate dead and/or viable cells depending on a stain applied (Breeuwer & Abee 
2000). On the other hand, the clumping of cells and loss of cells after fixation during 
staining may distort microscopic counts. Often microscopy is combined with 
fluorescent in situ hybridisation (FISH), which enables the identification and 
enumeration of selected bacteria (Amann et al. 1995).    
5.2. Culture method 
Traditionally culture method has been regarded as the golden standard for studying 
bacteria. It is notable that it is the only way to get bacterial isolates for further studies. 
The focus of the analysis of the intestinal microbiota has been on the enumeration and 
identification of numerically predominant cultivable faecal species (Holdeman et al.
1976, Finegold et al. 1983, Moore & Moore 1995). However, up to 60-80% of the 
mammal microbiota cannot be cultured and has not been characterised and identified 
(Moore & Holdeman 1974, Wilson & Blitchington 1996, Suau et al. 1999). The 
cultivable fraction is, however, relatively high compared to most other microbial 
ecosystems such as environmental biofilms and activated-sludge flocks (Amann et al.
1995). Uncultured microbes fail to grow on artificial agar media used in the culture as 
their suitable growth conditions, i.e. combination of nutrients, media, atmosphere, or 
necessary interactions with the host cells or other microorganisms, are not known or 
the cells are stressed or nonviable. In addition, the selective culture media used are 
either not selective enough or are too selective supporting the growth of only part of 
the microbes, and some microbes prevent the growth of others, and some are 
misidentified (Nelson & George 1995, Hartemink & Rombouts 1999). Thus the 
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culture result may not always give a truly representative picture of the microbiota 
studied. Culture method is also regarded as time-consuming and laborious. Despite 
the limitations, culture methods have successfully provided us the basic knowledge of 
clinically important microbes and intestinal ecosystem, and culture remains an 
indispensable tool for clinical microbiology.  
The identification of isolated bacteria has traditionally relied on morphological, 
physiological and biochemical characteristics. This phenotypic characterisation based 
on cellular and colonial morphology, growth requirements and characteristics, 
fermentation profiles etc. has weaknesses connected to the poor reproducibility, 
ambiguity because of plasticity of bacterial growth and poor discriminatory power 
(McCartney 2002). Likewise, molecular-based genetic characterisation carries 
limitations. Thus there is often need to combine phenotypic with genotypic 
characterisation (polyphenic approach). 
5.3. Molecular biological methods 
Detection and identification 
Alternatively, culture-independent molecular methods have been introduced and 
notable amounts of DNA originating from uncultivable bacteria have been extracted, 
analysed and classified. Molecular methods are recognised as a standard phylogenetic 
classification tool (Stackebrandt et al. 1994). They may offer more rapid and reliable 
identification than culture because the identification is based on the composition of 
nucleic acids rather than on the genomic expression under given culture conditions, 
and the DNA can originate from living or dead cells (Nissen & Dainty 1995, Tannock
et al. 2004). The applicability of molecular methods ranges from identification or 
detection of single bacterial species to characterisation of compex microbiotas, and 
molecular techniques have been applied in analysing evolutionary relatedness of 
different bacteria, in bacterial diversity studies, enumeration of bacterial groups, 
especially of extremely fastidious organisms, monitoring specific bacterial 
populations, and identification of bacterial isolates (McCartney 2002).  
Molecular methods are based mainly on detection of ribosomal RNA (rRNA) or 
ribosomal DNA (rDNA; DNA encoding the rRNA). The probes for target DNA 
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sequences can be designed for detecting bacteria on different phylogenetic levels from 
major genera or the group level to the species or even strain-specific level depending 
on the type of the study ranging from gut ecology studies to tracking specific 
probiotics or pathogens (Charteris et al. 1997, Franks et al. 1998). Highly conserved 
regions of ribosome can be used for designing universal probes and different variable 
regions for specific/targeted probes. Several thousands of 16S rDNA sequences 
including numerous uncultured bacteria are freely available in genomic databanks. 
The target DNA can be detected using various PCR-based methods or dot blot 
hybridisation with specific synthetic oligonucleotide probes or using fixed bacterial 
cells by fluorescent in situ hybridisation (FISH) combined with flow cytometry or 
microscopic analysis (Amann et al. 1995, Wang et al. 1996, Wilson & Blitchington 
1996, Lin et al. 1997). Quantitative PCR allows quantification of all DNA fragments 
detected by PCR using specific controls of known quantity giving an estimate of the 
number of target microorganisms in the sample (Doungudomdacha et al. 2001, Sanz 
et al. 2004). Using multiplex PCR several target regions can be multiplied in single 
reaction with all necessary primers (García et al. 1998).  
Population fingerprinting 
In general, fingerprinting techniques for studying bacterial communities within 
ecosystem are based on PCR and generate profiles representing the sequence diversity 
within the population (Zoetendal et al. 2004). Molecular fingerprinting techniques 
allow rapid assessment of the predominant bacterial species present in a sample and 
simultaneous analysis of multiple samples, and is well suited to studying changes in 
individual microbial communities over time (Suchodolski et al. 2004). Studies using 
rRNA are thought to reflect also the metabolic activity of bacteria; in hydridisation the 
ribosomal number is thought to be comparable to the number of active cells (Felske et 
al. 1997, Rigottier-Gois et al. 2003). TGGE (temperature gradient gel electrophoresis) 
or DGGE (denaturing gradient gel electrophoresis) can be used for creating bacterial 
profiles that can be compared using similarity percentages and dendrograms (Satokari
et al. 2003, Muyzer et al. 1993). TGGE has high sensitivity for detecting sequence 
differences (Muyzer et al. 1993). The composition of individual rDNA genes can also 
be sequenced and analysed using cloning libraries (Suau et al. 1999) or profiled using 
probing grids, checkerboard hybridisation (O’Sullivan 1999) or DNA microarrays 
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(Wilson et al. 2002). Sequencing of single PCR clones is a laborious and expensive 
procedure but allows immediate discrimination between bacterial species.
Like culture, molecular methods carry limitations such as PCR biases, laborious 
processing at the species level, requirements for a clone library or sequence 
information, semi-quantitative results, and expensive machinery and reagents 
(Zoetendal et al. 2004). The biggest challenge in molecular methods lies in the 
quantification of different microbial groups and determining their functionality, 
activity and dynamics within the diverse microbial populations (Sghir et al. 2000, 
McCartney 2002).  
5.4. Molecular typing methods 
Molecular methods are widely used for typing of cultured isolates. The most common 
molecular typing methods are plasmid profiling, pulsed-field electrophoresis (PFGE), 
multilocus enzyme electrophoresis (MLEE), ribotyping and random amplification of 
polymorphic DNA (RAPD-PCR, AP-PCR) (O’Sullivan 2000, Tannock 2001). These 
typing methods are applicable to numerous bacterial genera and can be used to 
distinguish bacterial isolates and to determine their relatedness. 
For epidemiologically related organisms PFGE has been proven a powerful 
discriminating tool, especially in food-born outbreaks and nosocomial infections (Grif
et al. 1998, Barrett et al. 1994, Diekema et al. 1997). PFGE has high discriminatory 
power and can differentiate e.g. between subtypes of O157:H7 associated with 
specific outbreak investigations, though for large-scale screening of O157:H7 isolates 
other fingerprinting methods such as repetitive extragenic palindromes (REP) and 
Box primers (rep-PCR), amplified fragment length polymorphism (AFLP) and 
ribotyping techniques are also applicable and less time consuming (Hahm et al. 2003). 
In PFGE the bacterial DNA is digested with restriction enzyme(s), the obtained 
fragments are separated electrophoretically and discrete banding patterns for each 
isolate are analysed. Strains typed with PFGE using standardised methodology can be 
compared internationally using clone libraries. The determination of relatedness of 
non-related organisms with PFGE is more tricky and cannot use the same criteria as 
for related organisms, since the relationship between restriction fragment banding 
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pattern and true genetic relatedness is poorly understood. In addition, PFGE includes 
always subjective decisions such as the selection of restriction enzyme(s), reading the 
restriction fragment banding pattern and choosing methods for analysing the data, and 
the interpretation of the results (Davis et al. 2003, Singer et al. 2004). Distracting 
variabilities in the patterns brought by transferable large plasmids can be eliminated 
by excluding fragments smaller than 160 kb from the analysis (Guyot et al. 1999). 
5.5. Indirect methods for analysing microbiota 
The microbiota, including cultivable and uncultivable species, can also be studied by 
indirect methods such as cellular fatty acid analysis (Peltonen et al. 1992), gas 
production (El Oufir et al. 1996), fermentation end product analysis (Topping & 
Clifton 2001) and enzyme activity profiling (Tannock 1999b, Gorbach & Bengt 
1986). Analysis of microbial biochemical activities gives an insight to the 
functionality of the microbiota without having to go through culture, isolation and 
identification steps. The in vitro methods, such as continuous flow cultures or batch 
fermentations, may not always be predictive of the actual in vivo situation, since the 
complex and dynamic interactions between the gut and the microbiota are difficult to 
mimic. The analysis of microbiota using bacterial metabolites is also complicated by 
their unstability as they are used by other microbes or absorbed.   
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6. Antimicrobial agents 
6.1. Classification of antimicrobial agents 
Infectious diseases can be controlled by treating a disease with drugs (antimicrobial 
therapy), or by preventing it by vaccines (immunisation) and healthy environment 
(sanitation, hygiene, nutrition). The most important drugs for treating microbial 
diseases are antimicrobial agents, representing one of the great triumphs of modern 
medicine. Antimicrobial agents are chemical substances produced by microorganisms 
which are active against other microorganisms. In prokaryotes cell wall synthesis, 
protein synthesis (bacterial ribosome), nucleic acid synthesis and cell membrane 
function are sufficiently different from those in human eukaryotic cells so that they 
can be targets for antibacterial agents without inhibition of the equivalent mammalian 
cell target (Mims et al. 1998). Many antimicrobial agents are natural microbial 
metabolic products or derivates of them, chemically modified to improve their 
properties. There are also totally synthetic antimicrobial agents. Some bacterial 
species are inherently resistant to some classes of antimicrobials because they lack a 
susceptible target, they are impermeable to the agent or they produce inactivating 
enzyme (Brock et al. 2003). Antimicrobial agents can be divided on the basis of the 
target site, chemical structure or function (Table 3).  
6.2. Emergence of antimicrobial resistance 
Antimicrobial resistance is a worldwide problem and numerous strategies to avoid the 
emergence of resistance have been designed. New antimicrobials are being introduced 
but as most of them are similar in structure to the previous ones, the emergence of 
resistance is often only a matter of time. Despite of the development of a wide range 
of different types of antimicrobial agents, extremely adaptable bacteria seem to 
develop resistance to each new agent that comes along. Use of antimicrobials always 
causes selective pressure leading to reduction in efficacy, and the huge overuse 
induces bacteria to acquire resistance faster than expected (Livermore 2003). 
Inappropriate use of antimicrobials brings potential risk to the patient as risks of 
toxicity and opportunistic infection or superinfection, and to the community by 
selection of resistant organisms and increased health care costs. Both appropriate use  
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Table 3. Classification of antimicrobial agents on the basis of the target of action 
(Mims et al. 1998). 
Inhibition of cell wall synthesis 
β-Lactams (ampicillin, cefotaxime, imipenem, aztreonam, cloxacillin) 
Glycopeptides (vancomycin, teikoplanin)   
Inhibitors of protein synthesis 
Aminoglycosides (gentamicin, streptomycin, kanamycin, neomycin, amikacin)   
Tetracyclines (tetracycline, doxycycline)   
Phenicols (chloramphenicol)   
Macrolides (erythromycin)   
Lincosamides (clindamycin, lincomycin)   
Streptogramins   
Fusidic acid   
Inhibitors of nucleic acid synthesis 
Sulfonamides   
Trimethoprim   
Quinolones (ciprofloxacin, norfloxacin, nalidixic acid)   
Rifamycin (rifampicin)   
Agents that affect DNA 
Nitroimidazoles (metronidazole)   
Inhibitors of cytoplasmic membrane function 
Polymyxins (colistin)   
of antimicrobials, including reduction in prescribing, and specific means to inhibit the 
emergence of resistance have been confronted. In addition to the mere use of 
antimicrobials the dissemination of resistance is connected to modern phenomena like 
large hospitals, institutional care of elderly, socialised care of children and youth in 
large units, and increasing travel (Holloway 2000, Sharma et al. 2005).  
There is still a lot to learn about the dynamics in the emergence, spread, and 
maintenance of resistance. It remains unclear why some bacteria, called hyper-
mutators, develop resistance very rapidly via mutation or DNA transfer while others 
remain susceptible, and why some resistant bacteria achieve epidemic spread while 
others do not. Potential factors in epidemic success include changes in bacterial 
properties such as adherence, desiccation and disinfectant tolerance, increased growth 
rate and adaptation to the fitness cost of resistance (Livermore 2003). When acquiring 
resistance by genomic alteration bacteria may lose some other character that may be 
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valuable when the antimicrobial selective pressure is absent. This burden or losing 
some feature is called fitness cost. Resistance mechanisms can be selected in both 
pathogenic and non-pathogenic bacteria, as shown in E. coli (Sunde & Sorum 1999). 
The largest reservoir of resistance has been thought to reside in the commensal gut 
microbiota (Guyot et al. 1999, Gulay et al. 2000, McDonald et al. 2001). 
Antimicrobial remains get into the intestine as residues that are not absorbed after oral 
administration, by diffusion from the surrounding tissue, and in bile via enterohepatic 
circulation (Nord & Heimdahl 1986b, Edlund & Nord 2000). After being enriched the 
resistance determinants may transfer within or between different bacterial genera e.g. 
between Bacteroides species and from gram-positive bacteria (Clostridium, 
Streptococcus, Enterococcus) to gram-negative bacteria (Bacteroides), and between 
bacteria originating from humans and animals (Nijsten et al. 1995, Shoemaker et al.
2001). 
6.3. Mechanisms of resistance 
As there are several mechanisms by which antibiotics influence bacteria, there are 
also several mechanisms by which bacteria acquire resistance. Resistance may result 
from a single random chromosomal mutation or a series of mutations leading to 
synthesis of altered protein. Spontaneous mutants that have competitive advantage in 
the presence of antibiotic pressure survive and multiply. Dissemination of resistance 
is, however, more often the result of acquirence of transmissible plasmids, 
transposons or gene cassettes in integrons carrying resistance genes, typically coding 
for resistance to several unrelated classes of antimicrobials (Hall 1997, Poole 2001). 
Mechanisms of resistance include target site alterations (lowered affinity), alterations 
in the access to the target site (impermeability, efflux pumps, alternative metabolic 
pathways) and inactivation of the drug (enzymes that modify or destroy the 
antimicrobial) (Brock et al. 2003).  
6.4. Adverse effects of antimicrobial agents  
An ideal antimicrobial agent would provide selective decontamination of the 
microbiota in a “gut friendly” manner, i.e. be active against pathogens and potentially 
pathogenic microbes but not against those that preserve the colonisation resistance. 
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Unfortunately only few, if any, available antimicrobials meet these criteria (Vollaard 
& Clasener 1994).  
The use of antimicrobials leads to selection of resistant organisms among pre-existing 
variants and may radically reduce the number of commensal anaerobes susceptible to 
antimicrobials like Bifidobacterium, Bacteroides and Lactobacillus leading to 
reduction in colonisation resistance. This opens new niches for the remaining resistant 
opportunistic bacteria or transient pathogens that normally have restricted growth. 
They may overgrow the intestine or move to another anatomical site where the host is 
unable to tolerate the colonisation, and pathogenic microbes such as C. difficile,
vancomycin-resistant enterococci, multidrug-resistant enterobacteria and Candida
may proliferate (Berg 1996, Falk et al. 1998, Sullivan et al. 2001). In patients with C. 
difficile-associated diarrhoea treated with metronidazole the proportion of facultative 
bacteria was increased with higher enterobacterial and enterococcal counts but also 
with greater diversity of clostridia and lactobacilli compared to healthy subjects 
(Hopkins & Macfarlane 2002).  
In addition to persisting infections and dissemination of resistant organisms, 
antibiotics predispose patients to serious clinical implications such as gastrointestinal 
disturbances and functional bowel symptoms, including diarrhoea, alterations in 
fermentation processes and reduction of short-chain fatty acid production (Bergogne-
Berezin 2000, Sullivan et al. 2001, Maxwell et al. 2002). Antibiotic-associated 
reduced carbohydrate metabolism in turn may result in osmotic diarrhoea, poor 
absorption of fatty acids, water and electrolytes, altered bile acid balance and 
cholesterol metabolism (Hashimoto et al. 1996, Bergogne-Berezin 2000). 
Antimicrobials may also have allergic and toxic effects on the mucosa, and the 
pharmacologic effect that macrolides have on intestinal motility may affect the 
pathogenesis of antibiotic-associated diarrhoea (Bergogne-Berezin 2000). Antibiotics 
may also trigger release of LPS (lipopolysaccharides) endotoxins from gram-negative 
organisms with possible deleterious effects (Prins et al. 1985). A combination of oral 
Candida albicans administration and Aspergillus fumigatus spore exposure has been 
shown to induce allergic airway disease in mice treated with antibiotics 
(cefoperazone) but not in untreated mice (Noverr et al. 2004). In clinical practise, 
antimicrobial resistance increases mortality, morbidity and health care costs. If the 
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patient is not responding to the antimicrobial treatment, the length of hospital stay is 
prolonged or repeated physician visits are needed, and secondary antimicrobials are 
often more expensive than the first line choices (Livermore 2003). 
Nosocomial infections 
Cross-contamination of resistant bacteria between individuals is especially significant 
in hospital environment where there is simultaneous selective pressure from several 
antibiotics and pathogens with lowered antimicrobial susceptibility may be enriched. 
In addition, a lot of patients with predisposing factors such as impaired 
immunosystem are exposed (Blazquez et al. 2000). Both hospitalised individuals and 
outpatiens are reported to frequently carry resistant bacteria regardless of antibiotic 
usage (Levy et al. 1988). The most common organisms causing infections of the 
urinary tract, surgical wounds, skin, respiratory and gastrointestinal tract, as well as 
systemic infections are staphylococci including MRSA, enterococci including VRE, 
E. coli, Klebsiella spp., Enterobacter spp., Pseudomonas spp., C. difficile and 
Candida spp. (Schaberg et al. 1991, Farr 2002, Biedenbach et al. 2004, Hull & Beck 
2004, D'Agata 2004). However, in many cases the infective strain originates from the 
patient’s own microbiota, thus hygienic measures cannot alone completely prevent 
nosocomial infections (Flynn et al. 1987), which are a widely acknowledged problem 
in both human and animal care, and are known to contribute significantly to mortality 
and health care costs. In Finnish patients over 50 000 nosocomial infections are 
reported annually, contributing to 2000-5000 deaths (Ora 2005). 
6.5. Use of antimicrobials in humans and animals  
Common use of antimicrobials of human importance in cattle and pets may increase 
the risk of transferring resistance from animal to human microbiota. Controversial 
arguments about antibiotic use in animals are being debated (Piddock 1996, Cook 
1997, Phillips et al. 2004, Guardabassi et al. 2004). Reductions in prescribing 
antimicrobials at a national level have been shown to reduce the prevalence of 
resistance within few years (Kristinsson 1997, Seppälä et al. 1997). However, 
reduction in antimicrobial usage does not always lead to reduced resistance. Resistant 
strains that are well adapted and carry minimal or no fitness cost because of the 
resistance determinant may not be displaced for a long period of time after the 
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exposure to antimicrobial agent has ceased. Strains that acquire resistance plasmid 
may initially grow more slowly than plasmid-free counterparts in the absence of 
selection pressure but after repeated subculture the difference may diminish as shown 
in tetracycline- and streptomycin-resistant E. coli and in tetracycline- and 
erythromycin-resistant Bacteroides (Bouma & Lenski 1988, Lenski 1997, Shoemaker
et al. 2001). 
6.6. β-Lactam antibiotics 
One of the most important groups of antimicrobial agents is β-lactam antibiotics, 
which are widely used in human and veterinary medicine (Livermore 1998). β-
Lactams account for 60% of antimicrobial consumption in Finland (National Medical 
Statistics, www.nam.fi). Most commonly used β-lactams include penicillins 
(ampicillin, piperacillin, cloxacillin), cephalosporins (cephalexin, cefuroxime, 
ceftriaxone), cephamycins (cefoxitin) and carbapenems (imipenem, meropenem). 
Their antimicrobial potential is based on their ability to interfere in the biosynthesis of 
the peptidoglycan layer of the bacterial cell wall.
Ampicillin 
Ampicillin (C16H19N3O4S) is relatively non-toxic and acid-stable and can be given 
orally or parenterally, parenterally in sodium salt form. Absorption of ampicillin is 
slower and more irregular than that of some of the esters (talampicillin) and analogs 
(amoxicillin) developed from it. The serum half-life of ampicillin in normal adults is 
0.7-1.4h (Neuvonen et al. 1994). Peak serum concentrations are obtained at about 2h 
after oral administration and right after parenteral administration. After an oral dose 
30% of ampicillin is exreted in urine within 6h, and after parenteral administration 
75% (Kucers & Bennett 1987). Low amounts are excreted also in bile. Unexcreted 
ampicillin is inactivated mainly in the liver (Kucers & Bennett 1987).  
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6.7. β-Lactamases 
The most common mechanism of resistance to β-lactams is bacterial β-lactamases, 
produced by a number of both gram-negative and gram-positive bacterial species. In 
addition to clinically important enterobacteria, β-lactamase production has been 
described in various anaerobic genera of the normal microbiota such as Bacteroides, 
Fusobacterium and Clostridium (Nord 1986a). β-Lactamases inactivate the antibiotic 
by hydrolysing the amide bond in the β-lactam ring. Numerous different β-
lactamases, both chromosomal and plasmid-mediated, have been described and they 
have been classified into four main groups and several subgroups on the basis of their 
function or structure (Livermore 1995, Bush et al. 1995, Bush & Jacoby 1997). 
Although hyperproduction of wild type β-lactamase induces resistance, the major 
contributors to resistance are thought to have arisen from single or multiple mutations 
in the structural β-lactamase genes (Reguera et al. 1991, Henquell et al. 1995, 
Belaaouaj et al. 1994, Brun et al. 1994). Resistance determinants are transferable and 
are found within a wide variety of plasmids (Thomson et al. 1993). In hospital 
environment ampicillin is considered a significant factor in maintaining selection 
pressure for the most prevalent plasmid mediated β-lactamases in gram-negative 
organisms (Burman et al. 1992).   
The predominant β-lactamases in gram-negative bacteria are TEM-type β-lactamases, 
coded by blaTEM genes, with TEM-1, TEM-2 and SHV-1 enzymes being the most 
common ones (Brinas et al. 2002). In E. coli TEM-1 is the predominating β-lactamase 
(Huovinen et al. 1988). These Ambler class A enzymes have traditionally been active 
against a broad spectrum of penicillins but evolution and selective pressure have 
conferred resistance to expanded-spectrum cephalosporins (extended-spectrum β-
lactamases; ESBLs) or to β-lactam-clavulanic acid combinations (inhibitor-resistant 
TEM; IRT) or to both (complex mutant TEM; CMT) (Medeiros 1997, Sirot et al.
1997, Poirel et al. 2004).  
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6.8. Inhibition of β-lactam resistance 
β-Lactamase inhibitors  
A way to avoid the microbial breakdown of β-lactams is the use of β-lactamase 
inhibitors simultaneously with β-lactams. β-Lactamase inhibitors such as clavulanic 
acid, sulbactam and tazobactam contain β-lactam ring as substrates for the β-
lactamase to which the “suicide inhibitor” binds preventing the enzyme to destroy the 
antibiotic. By themselves β-lactamase inhibitors have only little therapeutic value. 
Bacteria are, however, acquiring mechanisms to overcome the action of many of these 
inhibitors and a constant designing of new inhibitors is required.  
Degradation of intestinal β-lactam residues  
Another strategy to fight the emergence of resistance is intra-intestinal inactivation of 
antimicrobials by degrading the leftover antibiotic accumulating in the intestine where 
it triggers resistance and quantitative changes within the abundant microbial 
population (de Vries-Hoepers et al. 1993, Van der Waaij & Nord 2000). By degrading 
the antibiotic residue the selective pressure is abolished and the gut microbiota and 
colonisation resistance remain unaffected during antimicrobial treatment.  
One way to bring β-lactamase to the intestine is by administrating β-lactamase-
producing bacteria into the gut. Many intestinal microbes produce β-lactamase and 
faecal preparations from healthy subjects have been shown to inactivate β-lactams 
with individual variation (Veringa & van der Waaij 1984, Welling & Groen 1990). 
Patients harbouring β-lactamase-producing intestinal bacteria have less β-lactam-
induced alterations in their microbiota (van der Waaij et al. 1986, Chachaty et al.
1992, Chachaty et al. 1993, Stark et al. 1995). In gnotobiotic mice detectable amounts 
of β-lactamase and inhibition of ceftriaxone activity were produced in the intestine by 
colonising the mice with a mixture of four β-lactamase-producing anaerobes 
(Bacteroides thetaiotaomicron, Clostridium clostridioforme, B. uniformis E9, B. 
uniformis V4E3) (Leonard et al. 1989).  
Administrating the β-lactamase as a purified enzyme enables accurate screening and 
evaluation of the effects of the administration providing knowledge of the dosage. 
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When given orally the enzyme should be in a form where it does not affect the 
therapeutic effect of the target antimicrobial, thus it should be active only in the 
intestine, and not be absorbed into the systemic circulation, and, on the other hand, 
resist proteolysis and remain active in the intestine. This can be achieved in oral 
administration by packing the enzyme in capsules that are targeted to release the 
enzyme in the lower gastrointestinal tract and not in the stomach, in e.g. pH-based 
manner. In the present study, we analysed the ability to inhibit antibiotic-induced 
changes in the gut with a product with the above-mentioned characteristics, called 
targeted recombinant oral β-lactamase (TRBL). TRBL has been shown to degrade 
ampicillin in the jejunum of beagle dogs in a dose dependent manner but not to enter 
the systemic circulation or affect the serum ampicillin levels after i.v. administration 
of ampicillin (Harmoinen et al. 2003). A commercially available β-lactamase is in use 
in animal husbandry to destroy penicillin residues in cow milk (Korycka-Dahl et al.
1985, Suomen eläinlääkkeet 2003) 
6.9. Testing antimicrobial susceptibility 
The antimicrobial susceptibility of bacteria can be determined in vitro by standardised 
methods such as disk diffusion method and broth or agar dilution assay (NCCLS 
2002). Disk diffusion method is convenient in screening of resistance phenotypes 
(presence of the resistance genes) while dilution assay determines the precise level of 
resistance. In disk diffusion method the size of growth-inhibiton zone around a filter 
paper disk containing the antibiotic on agar plate determines the susceptibility of the 
culture, and in antimicrobial dilution assay minimal inhibitory concentration (MIC) is 
determined as inhibition of growth within a series of antibiotic dilutions in broth or on 
agar. MIC can also be tested on agar using commercial E-test strips containing stable 
increasing antibiotic gradient producing a growth-inhibition ellipse.  
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AIMS OF THE STUDY 
The purpose of the study was to examine in detail the microbiota in the upper and 
lower part of canine intestine. The samples were collected before, during and after 
ampicillin treatment with or without simultaneous β-lactamase administration and 
analysed using both traditional culture method and molecular methods. When 
designing the study we hypothesised that (1) jejunal and faecal microbiota differ 
significantly from each other, (2) ampicillin administration has dramatic effects on the 
composition and counts of the microbiota and on the susceptibility of the coliforms, 
(3) oral targeted β-lactamase inactivates intestinal ampicillin, inhibits the ampicillin-
induced changes and preserves colonisation resistance, (4) shifts in coliform 
population can be followed using resistance data and PFGE (pulsed-field gel 
electrophoresis) typing. 
The specific aims of the study were to: 
(I) Compare the cultivable canine microbiota in the jejunum to that in faeces. 
(II) Analyse the ability of β-lactamase administration to prevent ampicillin-
induced emergence of resistance in dogs during ampicillin treatment 
monitored by performing faecal bacterial culture combined to susceptibility 
testing, performing TGGE (temperature gradient gel electrophoresis) for 
dominant faecal bacterial groups and by determining the quantity of TEM-type 
β-lactamase-producing faecal bacteria by PCR and by following ampicillin 
levels in serum and jejunum. 
(III) Characterise canine jejunal and faecal coliform populations, their species 
variability and resistance patterns in the three treatment groups. 
(IV) Determine the genetic relatedness of coliform populations in the three 
treatment groups monitored by resistance patterns and PFGE typing. 
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MATERIALS AND METHODS 
1. Study design 
In the present study, healthy male laboratory beagles with permanent jejunal fistula 
were used. The dogs were obtained from Harlan-Winkelmann Gmbh (Borchen, 
Germany) and National Laboratory Animal Center (University of Kuopio, Finland). 
Their age was between 1 and 3 years and weight between 12 and 19 kg. The dogs 
were fistula operated and kept in the premises of the Department of Clinical 
Veterinary Sciences (Faculty of Veterinary Medicine, University of Helsinki). An 
intussuscepted nipple valve fistula was surgically inserted 170 cm distal to the pyrolus 
(Harmoinen 2004). The dogs were kept individually, fed with commercial dog food 
(Pedigree?, Waltham?, Masterfoods, Helsinki, Finland) and taken for walks in the 
same premises. Coprophagy was avoided by cleaning faeces from the premise after 
each dog had been taken out. The local ethics committee for animal experiment action 
in Helsinki, Finland approved the study.   
For a pilot study 6 beagles were randomised into 3 treatment groups, 2 in each, 
receiving ampicillin and placebo, ampicillin and targeted recombinant β-lactamase 
(TRBL) or only placebo. For the final study a new group of 18 beagles were similarly 
randomised into 3 treatment groups, 6 in each, but instead of 20 mg/kg of ampicillin 
for 10 days they received 40 mg/kg for 14 days (Table 1). The baseline samples were 
collected on day 0 and the follow-up samples 2 weeks after the treatment period 
(Table 2). Ampicillin sodium (A-PEN?, Orion Pharma, Espoo, Finland) or placebo 
(Natrosteril?, Orion Pharma) was administered i.v. 4 times a day 30 min after feeding 
and TRBL or placebo capsules were administered 20 and 27 min after feeding. 
Because of the different dosing of the ampicillin, the pilot study samples were 
excluded from the resistance studies (II, III, IV) but all baseline samples and all 
consecutive samples from the dogs receiving only placebo were included in the 
comparison study (I).    
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Table 1. Dosages used in the resistance studies for the 18 beagles. 
Treatment Amp / Pla Amp / TRBL Placebo 
Ampicillin (i.v.) 40 mg/kg 40 mg/kg 0 
TRBL (p.o.) 0 0.6 mg/kg 0 
Number of dogs 6 6 6 
Table 2. Sample collection timetable. 
Time point  Day 
Baseline 0 
During treatment 4, 10, 14 
Follow-up 28 
TRBL (targeted recombinant β-lactamase) 
In the designing of the oral β-lactamase the recombinant β-lactamase (Pen P protein) 
of Bacillus licheniformis 749/C was used as a model enzyme (Neugebauer 1981). The 
purified and freeze-dried targeted recombinant β-lactamase (TRBL) enzyme (Ipsat 
Therapies Ltd., Espoo, Finland) was released in gastrointestinal tract from enteric-
coated pellets in a time and pH-controlled form (Röhm GmbH & Co KG, Pharma 
Polymers, Darmstadt, Germany) (Harmoinen et al. 2003). The capsule is targeted to 
dissolve above pH 5.5, aimed to release the enzyme in the jejunum.  
2. Study animals and sample collection 
For study I jejunal and faecal baseline samples from 6 dogs in the pilot study and 16 
dogs in the final study were included, 2 dogs from the final study with no jejunal 
samples were excluded. In addition, all samples from 7 of the dogs receiving placebo 
treatment were included. For study II all faecal samples from the 18 beagles recruited 
for the final study were included. For studies III and IV all jejunal and faecal samples 
from the 18 beagles recruited for the final study were included. 
The serum and jejunal samples were collected 1 h after the first antibiotic 
administration of the day. The faecal samples were collected within 1 h of defecation. 
All samples were immediately frozen at -70°C. A total of 92 jejunal and 102 faecal 
samples were collected. The jejunal samples were not available from 2 dogs. The 
samples were processed in blinded manner, i.e. the Anaerobe Reference Laboratory 
personnel did not know from which treatment group the samples originated.
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3. Study location 
The dogs were operated and kept at the Department of Clinical Veterinary Sciences, 
Faculty of Veterinary Medicine, University of Helsinki, Finland. Parallel samples 
were analysed simultaneously using different methods in several different locations 
(Table 3). Bacterial culture, coliform identification, susceptibility testing and PFGE 
were performed at the Anaerobe Reference Laboratory, Department of Bacterial and 
Inflammatory Diseases, National Public Health Institute, Helsinki, Finland, whereas 
TGGE and PCR for TEM were performed at Microscreen BV, Groening, The 
Netherlands. Ampicillin concentrations in serum and jejunal samples were analysed at 
Yhtyneet Laboratoriot Oy (United Laboratories Ltd.), Helsinki, Finland. Statistical 
analyses were performed at each corresponding study location excluding Yhtyneet 
Laboratoriot. 
Table 3. Methods used.  
Method Target Sample material 
Bacterial culture Bacterial profiles, total counts, 
group/species level 
identification 
Jejunal chyme, faeces 
Susceptibility testing Antibiograms Jejunal and faecal 
coliform isolates 
PFGE typing  Genetic relatedness Jejunal and faecal E. coli
isolates 
TGGE Bacterial profiles Faeces 
TEM-PCR Amount of resistance gene Faeces 
High performance liquid 
chromatography (HPLC) 
Ampicillin concentration Jejunal chyme, serum 
4. Bacterial culture 
All samples from each animal were processed in parallel in order to ease the 
comparison between the 2 sample types and between consecutive samples. Small 
intestine fluid and faeces were thawed and homogenised, pH was measured (Benchtop 
420 pH Meter, Orion) and the sample consistency, colour and odour were recorded. 
The homogenates were serially diluted (10-1-10-7) in prereduced peptone-yeast extract 
broth with pH 7.0. An extensive series of dilutions together with the undiluted sample 
(10 μl or 100 μl) were plated onto several non-selective and selective agar media and 
incubated at 35°C as appropriate (Table 4). Anaerobiosis was induced in anaerobic  
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jars filled by the evacuation-replacement technique (Anoxomat WS8000, Mart B.V., 
Lichtenvoorde, Netherlands) with gas mixture (90% N2, 5% CO2, 5% H2). The exposure 
time to air was minimized throughout the procedure with careful planning and 
preparations, including the use of prereduced dilution broth and agar plates kept in 
anaerobic conditions 18 h prior to their use. 
The total counts and main groups of aerobic and anaerobic bacteria and yeasts were 
enumerated (the detection limit 102 CFU/g), different colony morphotypes were recorded 
with a stereomicroscope and isolated and identified by established methods. The isolates 
were picked according to differing morphologies, not on the amount of colonies on the 
plate or assumed importance of a finding. The identification scheme included 
aerotolerance testing, gram staining, spot and screening tests (catalase, indole, nitrate, 
lecitinase, lipase, pigment), special antimicrobial potency disk patterns (vancomycin, 
kanamycin, colistin, sodium polyanethol sulfonate, penicillin, oxgall), biochemical tests 
(carbohydrate fermentation, enzyme detection) and metabolic end-product analysis by 
gas-liquid chromatography after peptone-yeast extract glucose broth culture (Jousimies-
Somer et al. 2002, Murray et al. 2003). The presence of C. difficile common antigen and 
toxin A in faeces was determined with a commercial kit (Triage C. difficile Panel, 
Biosite, San Diego, CA) according to the manufacturer’s instructions. For unclassified 
clostridia resembling C. difficile, genes encoding 16S rRNA were amplified and 
sequenced with the primers fD1 Mod and 533r by the method of Jalava et al. (1995) and 
compared to the GenBank database. The microbial composition and counts between 
different sampling days, different treatment groups and between corresponding jejunal 
and faecal samples were compared.
5. Identification, susceptibility testing and PFGE typing of coliforms 
From each sample ten colonies or, if less, as many as possible of coliformic colonies 
(aerobic fermentative gram-negative rods) were isolated from Blood agar and CLED agar 
plates with optimal growth, and sub-cultured for further identification (Murray et al.
2003) and susceptibility testing (NCCLS 2002). The isolates were picked at random but
all visibly different colonies were included to get a representative selection of the 
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coliform population. The resistant isolates may not present the most common 
morphologic phenotype nor differ by e.g. lactose fermentation profile (Levy et al. 1988). 
The species level identification of coliforms was performed with spot tests (catalase, 
indole, oxidase), an individual diagnostic tablet of β-glucuronidase (Rosco, Taastrup, 
Denmark) and with the Api 20E kit test (bioMérieux, Marcy l’Etoile, France). 
For all isolated coliforms the resistance to several classes of antimicrobials including 
penicillins (ampicillin 10 μg), carbapenems (meropenem 10 μg), tetracyclines 
(tetracycline 30 μg), folate pathway inhibitors (trimethoprim 5 μg, trimethoprim/ 
sulfamethoxazole 24 μg), aminoglycosides (gentamicin 10 μg), quinolones (ciprofloxacin 
5 μg), and cephems (cephalothin 30 μg, cefotaxime 30 μg) was tested (Oxoid, 
Hampshire, England). The susceptibility was determined using the disk diffusion method 
as recommended by the National Committee for Clinical Laboratory Standards (NCCLS 
2002) on Müller Hinton agar inoculated with swabs dipped in bacterial suspension of 0.5 
McFarland with 16-18 h incubation. E. coli ATCC 25922 was used as a control strain. 
The selected E. coli isolates were typed using pulsed-field gel electrophoresis (PFGE) as 
described by Saari et al. (2001). The selected strains presented all different resistance 
patterns present in each dog at each time point. Bacterial suspension with A600 of 0.300 
was done in TEN buffer and embedded in 1.8% agarose (InCert Agarose, BioWhittaker 
Molecular Applications, Inc., Denmark) to prevent mechanical damage to the bacterial 
chromosome, lysed with proteinase K (0.5 mg/ml) (Roche, Mannheim, Germany) in ES 
buffer overnight at +50°C, washed to remove the protein digestion products, and the 
DNA was digested at +37°C overnight with restriction endonuclease XbaI (New England 
Biolabs, Beverly, MA) that cuts DNA infrequently. The blocks were run in 1% agarose 
gel (Seakem Gold Agarose, BioWhittaker Molecular Applications, Inc., Denmark) in 0.5 
x TBE buffer (6V/cm, 120°, 14°C, 21h, pulse times 5-40s) to resolve the restriction 
fragments into different patterns of discrete bands. The electrophoretic apparatus switches 
the direction of the current as programmed causing the fragments to reorientate between 
movements. As the swiftness of the reorientation is dependent on the size of the 
fragments this intensifies the separation of fragments with small difference in size. The 
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gels were stained with ethidium bromide (10μl EtBr / 200ml TBE, 30 min) and 
photographed under UV-light (Alpha Imager, Alpha Innotech, San Leandro, CA). The 
images were analysed using the Bionumerics version 3.0 cluster analysis with Dice 
similarity indices (1% position tolerance, UPGMA) (Applied Maths BVBA, Austin, 
Texas). The genetic relatedness of the strains based on PFGE profiles (fingerprint 
patterns) was interpreted as recommended by Tenover et al. (1995). 
6. TGGE (temperature gradient gel electrophoresis) 
TGGE was used to assess the bacterial profile and diversity with a molecular approach, 
based on the sequence variability of the V6 toV8 regions of the 16S rRNA. TGGE was 
performed as described by Muyzer et al. (1993) using primers P16S968GCF and 
P16S1401R. Briefly, 50 mg of faeces was homogenised and the bacterial DNA was 
extracted. PCR reaction was performed using Invitrogen’s Taq DNA polymerase kit and 
PTC-200 PCR system (MJ-Research). A temperature gradient was established in 
polyacrylamide gel in parallel to an electric field. The gels were run (200 V, 60°C) in 
1.5% (wt/vol) agarose gel using TGGE MAXI system (Biometra, Germany). The 
amplified DNA fragments migrate differently according to their size and sequence 
specific melting behaviour (thermal stability) to the point where the conformation of the 
double stranded DNA changes. As the sequences in TGGE are all the same length the 
fragments separate in sequence specific manner, and a profile reflecting the prominent 
bacterial content of the sample is achieved. Fragments containing more A-T pairs are 
more vulnerable to temperature than those containing C-G pairs. To prevent the double 
stranded DNA to denature into single stranded DNA, a C-G rich segment is added to one 
of the primers. The gels were silver stained with AgNO3 by the method of Cairns and 
Murray (1994). The individually unique TGGE profiles obtained from the same 
individual on different sampling days were compared using similarity percentages and 
constructing dendrograms using GelCompar II software (Applied Maths, Belgium). 
7. PCR for detecting TEM gene  
The emergence of ampicillin resistance was evaluated also by performing quantitative 
real-time PCR of the TEM β-lactamase gene by quantifying the percentage of TEM 
53
producing bacteria of the total number of bacteria as proportions of DNA in the faecal 
samples. The PCR was designed for V6-V8 region of the 16S rRNA gene using TemA, 
TemB, TemE and TemH primers and SYBR green (Molecular Probes, AA Leiden, 
Netherlands) as fluorogenic marker. The bacterial total count was set as 100% and the 
amount of Tem sequences was compared to the total bacterial DNA. SYBR Green is a 
higly sensitive (for low numbers of target DNA amplification product) fluorescent dye 
specific for double-stranded DNA. During quantitative PCR reaction, SYBR Green dye 
binds to the amplified double-stranded PCR products and emits a fluorescent signal. 
Detection of this signal enables direct quantitation of amplified DNA by comparing the 
fluorescence to known standards. 
8. Measurement of ampicillin concentration  
In addition to microbial analyses, the serum (quantification limit 1.0 μg /ml) and jejunal 
(0.5 μg /ml) ampicillin levels were monitored in samples collected 1 h after the first 
antibiotic administration of the day. The ampicillin analysis was performed using high 
performance liquid chromatography (HPLC) by modification of the method of Vree et al.
(1978). HPLC analysis is based on the different migration rates of different compounds in 
particular chromatographic conditions. A characteristic peak at expected retention time is 
observed in a chromatograph for each compound in the injected sample. The 
quantification of the compound the peak presents is calculated from the area under the 
peak using standard calibration curve with known amounts of the compound.   
The jejunal samples were frozen (-70°C) until analysis when they were thawed, mixed by 
vortex and centrifuged (4°C, 1800 g, 15 min). The tubes were placed on ice and the 
supernatant was transferred to a cooled glass beaker, diluted in cooled NaCl, filtered 
trough 0.22 μm filters and frozen (-70°C) until analysed by HPLC. The serum samples 
were centrifuged (1000g, 15 min) and frozen until analysed. A Hewlett Packard 1100 
HPLC instrument with a diode-array detector was used as follows: Supelco Discovery RP 
Amide C16 column, 2 mobile phases at a flow-rate of 1.0 ml/min (96 % phosphate 
buffer, pH 6.0 and 4 % acetonitrile for quantitative determinations, 96 % 
ammoniumacetate, pH 5.2 and 4 % acetonitrile for spectral identification), detection at 
229 nm for ampicillin and 296 nm for internal standard (benzylpenicillin procain).
54
9. Statistical analysis 
The statistical analyses for culture-based methods were performed using the SPSS 11.5 
(SPSS, Chicago, IL, USA) and Epi Info 6 Statcalc (CDC, Atlanta, GA USA) software for 
Windows. The pH values of the samples and number of isolates in the 2 sample types 
were compared by the paired samples t-test and frequencies of different bacteria by 
Statcalc single table tests. The differences between the bacterial counts were assessed by 
the Wilcoxon signed rank test (non parametric). A P-value <0.05 was considered 
statistically significant. 
For the molecular methods the data analyses were performed with Statistical Analysis 
System (SAS) software (version 8.1, 2000; SAS Institute Inc.). The PROC MIXED 
program in SAS software was used to analyse the repeated measurements of the percent 
similarities of the faecal flora determined by TGGE. The nonparametric analysis of 
variance and ANOVA were used to compare the ampicillin concentrations and TEM gene 
levels. A P-value < 0.01 was considered statistically significant.  
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RESULTS 
1. Jejunal versus faecal cultivable microbiota (I) 
The microbial findings of jejunal chyme and corresponding faecal samples were 
compared. Jejunal fluid samples varied markedly in viscosity, texture, and color 
(mucous/running, reddish/brown/greenish). The odor of the fluid was mild and often 
slightly sweet. All samples were culture-positive: all growth in jejunal samples was 
recorded and identified, while from faecal samples only bacterial groups in dilutions >10-
5—6 could usually be isolated and identified. Because of relatively low bacterial counts, 
different colony types were technically easier to isolate from the jejunal than faecal 
samples. Significant differences between the two sample types were found both 
qualitatively and quantitatively. The total cultivable bacterial counts in the jejunum were 
outnumbered by the counts in faeces (102-6 vs. 108-11 cfu/g, respectively). Notably, 
bacterial counts in 9% (2/22) jejunal baseline samples reached 106 cfu/g and 27% (6/22) 
reached 105 cfu/g with varied dominating species. Anaerobes covered a significantly 
lower proportion of the total bacterial count in the jejunum compared to faeces (48% vs. 
79%, respectively, P=0.004), and significantly less bacterial genera/species were found in 
the jejunum than in faeces (7 vs. 12, respectively, P<0.001).  
The proportions of different cultivable bacteria differed significantly between the jejunal 
and faecal samples as presented in Figure 1 and 2. Altogether 25% of the bacteria found 
in the jejunum were not detected in the corresponding faecal sample, or 45% of the faecal 
findings in the jejunum. In addition, several microbes such as staphylococci, other 
catalase-producing gram-positive cocci, non-fermentative gram-negative rods and yeasts 
were more frequent in the jejunum than in faeces, and some bacteria (neisseria, 
micrococci), most likely of orophraryngeal origin, were detected only in the jejunum. 
Although gram-negative organisms had on average a higher prevalence in the faecal than 
jejunal samples (53% vs. 28%), the proportion of gram-negative organisms of the total 
count was higher in the jejunum than in faeces (28% vs 3%). The dominating cultivable 
species (those with highest counts) were the same in the corresponding faecal and jejunal 
sample in 5/22 (23%) dogs. In faeces, the dominating species were similar between 
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different dogs (anaerobic gram-positive cocci in 10 and streptococci in 5 dogs), whereas 
the dominating species isolated from jejunal chyme varied between the dogs (anaerobic 
gram-positive cocci in 4, staphylococci in 4, aerobic gram-positive rods in 4 dogs). 
A group of unclassified clostridia (“Clostridium hiranonis- like” organisms) was found in 
just one jejunal sample but in 18/22 (82%) of faecal samples (P<0.001). The isolates 
resembled C. difficile biochemically whereas the 16S rRNA sequence analysis was 99% 
identical to C. hiranonis but the isolates were biochemically different from C. hiranonis.
Among the Bacteroides fragilis group B. fragilis was the dominating species in the 
jejunum while in faeces it was just one species among others, B. vulgatus and B. caccae
being at least as common. Out of the 166 faecal coliform isolates E. coli covered 98% 
while of the 9 coliform isolates from the jejunum 6 (67%) were Citrobacter spp. and 2 
(22%) E. coli.
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Figure 1. Prevalence of cultivable anaerobic and aerobic/facultative bacteria and yeasts 
in the jejunum and faeces at baseline (Study I). Epi Info 6 single table test:  
* P<0.05, **P<0.001.
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Figure 2. Median counts (log cfu/g) of different cultivable bacterial groups in the 
jejunum and faeces at baseline (Study I).
2. Stability of the cultivable intestinal microbiota (I) 
Five consecutive samples from 7 of the dogs, collected during a month, were compared 
with each other. The predominant jejunal species varied between the dogs and between 
the consecutive samples while the faecal microbiota was more stable and more similar 
between the dogs. The findings in the consecutive samples were found repeatedly in 42% 
of the jejunal samples and in 60% of the faecal samples. In faecal samples the variation in 
time was biggest among subdominant species close to the detection limit while in jejunal 
samples all species varied. Several microbial groups or species such as streptococci, 
yeasts, gram-negative anaerobic and aerobic cocci, gram-positive anaerobic cocci, C.
perfringens and staphylococci were never found in all consecutive jejunal samples of a 
dog. In faecal samples dominant species remained stable though their counts fluctuated. 
3. Effects of ampicillin and prevention of them by TRBL (II, III) 
The effects of ampicillin were followed in the group receiving ampicillin + placebo 
(Amp/Pla) (Table 1). Significant changes in the cultivable microbial composition and in 
the resistance rates were recorded in this treatment group, while oral β-lactamase 
preserved the faecal microbiota during the ampicillin treatment, monitored as significant 
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differences between the groups receiving ampicillin + placebo and ampicillin + TRBL 
(Amp/TRBL), and, on the other hand, no marked differences between Amp/TRBL and 
placebo + placebo (Placebo) groups. The effects with similar differences between 
treatment groups were found by all methods used: culture, susceptibility testing, TGGE 
and TEM-PCR. 
Table 1. The effects of ampicillin in the Amp / Pla group. 
Method Effect detected in Amp/pla group 
Bacterial culture Altered bacterial profiles, decreased total counts 
Susceptibility testing Significant increase in ampicillin (multi)resistance 
TGGE Altered bacterial profiles (drop in similarity 
percentage) 
TEM-PCR Increased amount of TEM resistance gene 
High performance liquid 
chromatography (HPLC)  
High serum and jejunal ampicillin concentrations 
3.1. Changes detected by culture (II, III) 
During the intervention the total faecal count of cultivable aerobes decreased significantly 
in the Amp/Pla group (P=0.003) whereas in the Amp/TRBL group the total counts 
remained fairly stable. Although the decrease in the anaerobic total count in the Amp/Pla 
group was not significant compared to the baseline, the anaerobic total count was 
significantly lower than in the Amp/TRBL group during the treatment (P=0.041). 
Decreased counts were recorded for streptococci, enterococci, clostridia and anaerobic 
gram-positive cocci, while aerobic and anaerobic gram-negative rods increased their 
proportion of the total count. 
3.2. Microbial shifts detected by TGGE (II) 
During the treatment the overall percentage similarity of the faecal microbiota, 
determined by TGGE, dropped to a significantly lower level in the Amp/Pla group (38-
53%) compared to the Amp/TRBL and Placebo groups (78-85%) (P<0.001). 
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3.3. Ampicillin concentrations (II) 
β-Lactamase had no effect on the ampicillin concentrations in serum; the concentrations 
were similar in the groups receiving ampicillin and placebo or ampicillin and TRBL 
(mean 17.7 vs. 18.0 μg/ml, respectively). No ampicillin was detected in the Placebo 
group.  
The ampicillin concentrations in the jejunum were significantly higher in the group 
receiving ampicillin and placebo than in the group receiving ampicillin and TRBL (mean 
26.3 vs. 1.5 μg/ml, respectively, P<0.0001). In the latter group β-lactamase had degraded 
the intestinal antibiotic residue. 
3.4. Change in TEM gene levels (II) 
The TEM gene levels (determined as the mean percentage of TEM gene of the total 
amount of DNA) were very low or undetectable in all dogs at baseline. During the 
treatment the proportion of TEM gene reached a significantly higher level in the Amp/pla 
group (>0.15%) than in the other groups (<0.025%) (P<0.001). 
4. Antimicrobial resistance in coliforms (II, III, IV) 
Altogether 982 (860 faecal, 122 jejunal) coliform isolates were collected, identified and 
tested against 9 antimicrobials. E. coli covered 87% (106/122) of the jejunal and 99% 
(855/860) of the fecal isolates. A total of 22 different resistance patterns, with 12 patterns 
displaying ampicillin resistance, were identified. Each sample displayed 2-3 (ranging 
between 1-6) different patterns. The 5 most common patterns covered 94% of the faecal 
and 77% of the jejunal isolates. 
4.1. Emergence of resistance in coliforms (II, III, IV)  
An increase in ampicillin resistance (multi-resistance) was detected in all treatment 
groups but the resistance rate was significantly higher in the Amp/Pla group than in the 
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other groups (P<0.001) (Figure 3). Ampicillin-resistant isolates were frequently resistant 
also to trimethoprim, trimethoprim/sulfamethoxazole, tetracycline and occasionally to 
cephalotin. None of the isolates were resistant to ciprofloxacin, meropenem, or 
cefotaxime. The overall resistance rates in the 3 treatment groups are presented in Figures 
4a-c. In the jejunal samples the pattern of increasing resistance was similar to faeces but, 
additionally, a significant increase was detected also in the number of jejunal coliforms 
available. During the treatment a total of 68 jejunal coliform isolates were obtained in the 
Amp/Pla group while in Amp/TRBL and Placebo groups there was no increase in the 
number of coliforms and only 16 and 15 isolates were obtained during the treatment, 
respectively.  
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Figure 4c. Placebo group.  
4.2. Assessing the relatedness of coliforms (IV) 
The relatedness of coliform isolates was determined using the identification results and 
resistance patterns in combination with PFGE typing. Selected 402 (339 faecal, 63 
jejunal) E. coli isolates were typed by PFGE and 25 different PFGE types were identified. 
Each dog harboured on average 5 (ranging between 2-8) different PFGE types during the 
28 days’ study period. The dogs shared several PFGE types. Ampicillin resistance was 
found in 6 different PFGE types in 9 different combinations of co-resistance (Table 2). 
None of the PFGE types was widely spread between the dogs in the different treatment 
groups but certain ampicillin-resistant PFGE types (F, G, E, A) were enriched in the 
Amp/Pla group where at least one new ampicillin-resistant PFGE type appeared in all 
dogs. In the Amp/TRBL group half of the dogs carried ampicillin resistant strains at 
baseline and during the treatment but among the other half no resistant strains were 
detected. In Placebo group new resistant strains appeared in 3 dogs during the treatment. 
Apart from the two strains in a single dog that seemed to acquire resistance during the 
Amp/pla treatment, the resistant strains enriched were most often selected from pre-
existing resistant strains.  
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Resistance pattern PFGE type Isolated from group 
Amp / 
Pla
Amp / 
TRBL 
Placebo 
Fully susceptible A, B, C, D, H, I, J, K, 
M, P, Q, R, S, T, U, V, 
X, Z, AA, ff* 
+ + + 
Amp, Tet, Tmp, Sxt G, E, E1 + + + 
Amp, Gen, Tmp, Sxt A, D, F, F1, F2 + + + 
Amp, Cef, Tet, Tmp, Sxt G + - - 
Amp, Cef, Tet, Tmp ff* - - + 
Amp, Cef, Tet ff* - - + 
Amp, Gen, Tet, Tmp, Sxt A + - - 
Amp, Cep, Tmp Q - + - 
Amp, Tet G, ff* - + + 
Amp, Tmp, Sxt G - +  
Tet, Tmp, Sxt A, E, L, P  + + + 
Tet A, BB, Y + + - 
Gen, Tmp F + - - 
Cef, Tet BB  + - - 
Tmp, Sxt L  - + - 
Tmp A - + + 
Sxt I - + - 
Gen D, O - - + 
Cef S - - + 
Table 2. Distribution of resistance patterns and PFGE types of the E. coli isolates. *ff, 
untypeable. Amp, ampicillin; Tet, tetracycline; Tmp, trimethoprim; Sxt, trimethoprim/ 
sulfamethoxazole; Gen, gentamicin; Cef, cephalothin. 
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DISCUSSION 
Characterisation of jejunal and faecal microbiota by culture 
The isolation and identification of all species present in a faecal sample is thought to be 
extremely demanding if not impossible. Regardless of the methodology chosen, only the 
predominant populations of the cultivable microbial groups can most often be monitored. 
Although the selectivity of currently available agar media is limited and requires further 
characterisation and identification methodology, our culture method proved to be 
sensitive enough to detect differences between the two sample types regardless of the 
restricted use of the species level identification. 
In the present study the nature of the small intestinal microbiota, differing markedly from 
that of the colon, was characterised as fairly simple and variable, consisting of only few 
species at a time with fluctuating counts compared to the rich and stable faecal 
microbiota. All samples were frozen (-70°C) without delay and processed later in 
parallel, however, the effect of freezing on the microbes of jejunal samples with varying 
texture has not been fully assessed. The jejunal bacterial counts in some of these healthy 
beagles crossed the typical limit for small intestinal overgrowth (105 cfu/ml) (Corazza et 
al. 1990, Stotzer et al. 1998). The counts were not so high repeatedly but all jejunal 
samples grew bacteria confirming the unreliability of diagnosis of overgrowth based on a 
single culture. In addition, this finding questions the feasibility of such a definitive limit. 
On the other hand, the jejunal samples in the present study were obtained without 
anesthesia shortly after feeding and may have been therefore exceptionally productive 
yielding high bacterial counts including anaerobes. It cannot, however, be excluded that 
the permanent fistula may in some individuals have had an effect on the intestinal 
motility and bacterial counts. 
The quantitative and qualitative relations within the cultivable microbiota were 
significantly different between the two sample types. Our observation is in agreement 
with previous findings reporting higher ratios of aerobes and differences in frequencies of 
gram-negative organisms in the upper human gut (jejunum, ileum and caecum) compared 
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to the colon and faeces (Gorbach et al. 1967, Justesen et al. 1984, Marteau et al. 2001). 
Oropharyngeal microbes have been reported to dominate in jejunal biopsies of humans 
(Sullivan et al. 2003), whereas E. coli and streptococci were the most common findings 
in the jejunum of 35 mongrel dogs (Thompson et al. 1998). Higher or comparable counts 
of fungi, staphylococci and lactobacilli have been reported in the human ileum than 
faeces (Gorbach et al. 1967). Similarly we found staphylococci, yeasts and also other 
catalase-producing cocci and non-fermentative gram-negative facultative rods more 
frequently in the canine jejunum than in faeces but less lactobacilli. Additionally, some 
species isolated from jejunal samples were undetected in faeces. Marteau et al. (2001) 
reported facultative bacteria to be as numerous as anaerobes in the human caecum. This 
seems to be true in the jejunum as well, as shown in the present stydy. B. fragilis proved 
to be the most frequent species of the B. fragilis group in the canine small intestine but 
not in faeces. In agreement with our observation, B. fragilis has been reported to be the 
most frequent isolate from mucosal surfaces of humans but not in colon contents 
(Namavar et al. 1989). In the present study the canine jejunal microbiota was also found 
to be less stable than the faecal microbiota. The canine duodenal microbiota monitored by 
DGGE profiles has been shown to differ more between individual dogs than between 
samples from the same dog (Suchodolski et al. 2004). The canine fecal bacterial DGGE 
profiles have individually unique and stable characteristic banding patterns (Simpson et
al. 2002).  
It is noteworthy that we found no C. difficile in contrast to some other animal studies 
(Marks et al. 2002, Buogo et al. 1995) but we detected instead a group of unclassified 
clostridia resembling C. difficile as part of the dominating faecal microbiota. In addition 
to strict anaerobes, facultative streptococci were among the dominating microbiota. Also, 
we found bifidobacteria more often than lactobacilli (in 64% vs. 32% of the dogs, 
respectively) while two recent studies on labrador and beagle dogs reported no 
bifidobacteria but numerous lactobacilli (Buddington 2003, Greetham et al. 2002). The 
lactic acid bacteria in fistulated dogs were recently characterised by Rinkinen et al.
(2004) with Streptococcus alactolyticus dominating, followed by Lactobacillus murinus
and L. reuteri.
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Comparison of culture to molecular methods 
Though molecular methods have brought new aspects to the phylogenetic and 
quantitative relations of different bacteria in the gut, culture-based and molecular-based 
profiling may not be contradictory and give often in general somewhat similar overview. 
Culture-based analyses may, however, give higher qualitative and quantitative 
fluctuations especially in the faecal microbiota compared to molecular methodology. 
Similar to our study, the vast fluctuation in canine small intestinal microbiota compared 
to faeces has been reported by both culture and DGGE reflecting genuine variation rather 
than weakness in sampling or analysis methodology (Willard et al. 1994, Delles et al.
1994, Harmoinen et al. 2001, Suchodolski et al. 2004). We found by culture in the canine 
faeces a relatively low mean proportion of Bacteroides (0.3%), a high proportion of 
anaerobic gram-positive cocci (30%) and clostridia (37%), a relatively high proportion of 
streptococci (19%) and relatively low proportion of bifidobacteria (4%) and 
enterobacteria (1%). Culture negativity or limited number of microbial findings may not 
always give an accurate picture of the number or consortia of microbes present. For 
example, cultures and microscopic examinations of oesophagal washes and biopsies have 
provided poor microbial yields but microbes in oesophageal biopsies detected by 
sequence based broad-range 16S rDNA are by a large majority (82%) cultivable bacterial 
species (Pajecki et al. 2002, Pei et al. 2004). 
Ampicillin-induced changes 
In the present study ampicillin was found to induce significant qualitative and 
quantitative changes and emergence of multi-resistant coliform strains among the canine 
intestinal microbiota. These phenomenona have been well documented for ampicillin and 
several other antimicrobials also in previous human studies (Nord 1986a, Black et al.
1991, Garau et al. 1999, Shanahan et al. 1994, Huovinen et al. 1995, Dradenovich et al.
2004). Among human faecal enterobacteria E. coli is the main carrier of resistance 
(Österblad et al. 2000). In the present study ampicillin resistance was most often 
combined to trimethoprim and trimethoprim/sulfamethoxazole resistance in canine 
strains. A similar combination of resistance occurs frequently, since transmissible 
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plasmids coding resistance to ampicillin and trimethoprim are common in human E. coli,
and selective pressure for either is likely to select resistance to both drugs (Amyes 1989, 
Magee et al. 1999). As shown previously, the screening of coliform susceptibility is a 
feasible and sensitive method to follow the steps in the emergence of resistance (Corpet 
1993). In the present study, to intensify the resistance screening, 10 isolates representing 
all colony morphotypes per sample were tested for resistance. Further, to overcome 
biases due to the culture method, molecular methods were used to follow the changes in 
resistance rates monitored as amounts of TEM gene. In addition, several samples during 
the treatment were analysed.  
Resistance within coliform populations  
PFGE typing revealed a considerable genetic heterogeneity within the ampicillin-resistant 
canine E. coli populations. Though digestion of DNA with more than one restriction 
enzyme could have increased the discriminatory power of the PFGE method and 
separated strains considered identical, the present analysis with one enzyme (XbaI) was 
successful in discriminating numerous genetically different clones with varying 
frequencies within a large number of related isolates in the three treatment groups. Dogs 
shared several clones but no single resistant strain was widely spread. Since the resistant 
strains were most often selected from the pre-existing microbiota or spread between dogs, 
and were genetically heterogeneous, several resistant types co-existed. The selection of 
resistant strains from the resident microbiota is thought to be more common than 
acquirance of a new resistance determinant in strains previously susceptible (Guyot et al.
1999, McDonald et al. 2001) as was the case also in the present study.  
Heterogeneity, constant shifts between strains within E. coli populations and sharing of 
common types has been reported in humans, dogs and cattle (Levy et al. 1988, Avery et 
al. 2004, Akiba et al. 1999, Münnich & Lübke-Becker 2004, Dradenovich et al. 2004). 
The appeared resistant strains replaced the PFGE types present at baseline in the dogs 
receiving ampicillin without β-lactamase but not in the other two groups.  
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Prevention of ampicillin-induced changes by TRBL 
Orally administered β-lactamase did not affect the ampicillin level in serum but degraded 
ampicillin in the intestine and prevented the ampicillin-induced changes in the intestinal 
microbiota. Colonisation resistance was reduced and multi-resistant coliforms colonised 
the jejunum only in dogs treated with ampicillin without β-lactamase but not in dogs 
treated with ampicillin with β-lactamase. The slight increase in resistance rates detected 
in the Amp/TRBL and Placebo groups could be due to the cross-contamination and 
spread of resistance determinants from the dogs in the Amp/pla group, since the dogs 
were not totally isolated from each other. Other possible sources of resistance 
determinants include food, environment, kennel facilities and personnel as reported also 
in other studies (Corpet 1987, Avery et al. 2004, de Graef 2004). Concurrent 
administration of antibiotic and β-lactamase could provide a new strategy to limit the 
emergence of resistance and spread of nosocomial pathogens, and reduce antibiotic-
associated diarrhoea. In addition to ampicillin, β-lactamase has shown to be applicaple to 
inhibit piperacillin-induced changes (Stiefel et al. 2003). 
Commensal microbes gradually overgrow the resistant strains when the selection pressure 
is absent (Trott et al. 2004). The restoration of the microbiota may, however, be slower 
than previously thought. The antibiotic-associated alterations in the microbiota can be 
detected for months or even up to 3 years after a single antibiotic course (Maxwell et al.
2002, Mangin et al. 1994, Sjölund et al. 2003). Antimicrobial resistance determinants are 
known to be transferable among the commensal microbiota (Gulay et al. 2000, Yates et 
al. 2004). In the present study, the microbiota had not recovered to the baseline 
configuration 2 weeks after the treatment. Although the bacterial counts and composition, 
TGGE profiles and TEM gene proportions resumed levels close to the baseline, the 
enriched or appeared ampicillin-resistant PFGE types in the Amp/pla and Placebo groups 
were still present and the proportion of resistant isolates was higher than at baseline. 
Future aspects
The next phase in studying combined ampicillin and β-lactamase administration would be 
a study trial in humans. Further phases in developing means to prevent antimicrobial 
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resistance using β-lactamase could include development of new β-lactamases targeted to 
other β-lactams.  
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KEY FINDINGS AND CONCLUSIONS  
To protect the indigenous microbiota in a safe and convenient manner the composition 
and functions of the microbiota should be well known and understood, and the desired 
changes, or their absense, as well as their magnitude and dimensions should be closely 
monitored with suitable methodology. The present study was carried out in order to 
develop the understanding of the jejunal microbial composition and stability, and to 
specify the dissimilarities between the jejunal and faecal microbiota. Another main focus 
of the study was to evaluate the ability of enzymatic inactivation of intestinal 
antimicrobial residues to inhibit antibiotic-induced adverse effects on the microbiota. 
The key findings were: 
I  Significant microbial differences between the jejunal and faecal findings were 
recorded in regard to the bacterial counts, species composition, species variability, 
stability, relations of gram-negative to gram-positive organisms and relations of aerobic 
to anaerobic microbes.  
II  Ampicillin-induced changes among the intestinal microbiota were inhibited to a 
significant extent by simultaneous oral β-lactamase administration.  
III  Ampicillin treatment without simultaneous β-lactamase administration induced 
the emergence of multi-resistant strains displaying numerous combinations of co-
resistance and significantly increased the colonisation of the jejunum with coliforms. The 
increase in resistance was markedly inhibited and the jejunal colonisation resistance was 
preserved when ampicillin treatment was combined to β-lactamase.  
IV  The emergence of resistance among intestinal coliforms was due to selection 
and/or dissemination of several genetically different strains rather than acquirance of 
resistance in previously susceptible strains or spread of single or few resistant strains 
between the dogs in different treatment groups.  
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Conclusions 
The small intestinal microbiota has individually unique features in regard to counts, 
species composition and variability of the microbes, differing markedly from those of 
faeces. Orally administered β-lactamase was shown to have potential in clinical use by 
inhibiting the emergence of resistance and preserving the microbiota during antimicrobial 
therapy. β-Lactamase can be beneficial in inhibiting the emergence and enrichment of 
resistant strains and in maintaining the colonisation resistance in jejunum during 
ampicillin-induced selection pressure. 
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